PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 26820216-6 2016 The ganglionic nicotinic receptor blocker, hexamethonium dichloride, attenuated the pressor response to Ang II, indicating that the cardiovascular sympathetic system is involved in the pressor effect of Ang II. Hexamethonium 43-67 angiotensinogen Rattus norvegicus 203-209 26746861-9 2016 The effects of relaxin-2 on RSNA and MAP were abolished by intravenous infusion of ganglionic blocker hexamethonium, and attenuated by AVP V1 receptor antagonist AAVP. Hexamethonium 102-115 relaxin 2 Homo sapiens 15-24 26820216-6 2016 The ganglionic nicotinic receptor blocker, hexamethonium dichloride, attenuated the pressor response to Ang II, indicating that the cardiovascular sympathetic system is involved in the pressor effect of Ang II. Hexamethonium 43-67 angiotensinogen Rattus norvegicus 104-110 26948539-5 2016 In conscious rats, unilateral BDNF (12.5ng) microinjections into the PVN increased mean arterial pressure (MAP) by 27+-1mmHg (P<0.001 vs vehicle), which was significantly attenuated by intracerebroventricular infusion of the Ang II-type-1 receptor (AT1R) antagonist losartan and by ganglionic blockade with intravenous hexamethonium infusion. Hexamethonium 322-335 brain-derived neurotrophic factor Rattus norvegicus 30-34 26948539-6 2016 In anesthetized rats, unilateral PVN microinjection of BDNF increased MAP by 31+-4mmHg (P<0.001 vs vehicle), which was prevented by PVN microinjection pretreatments with the high-affinity BDNF receptor TrkB antagonist ANA-12, losartan, the angiotensin converting enzyme inhibitor lisinopril, or by intravenous hexamethonium. Hexamethonium 313-326 brain-derived neurotrophic factor Rattus norvegicus 55-59 27028622-10 2016 Nicotine increased the Bax/Bcl-2 ratio, which was attenuated by N-acetyl-L-cysteine, the NF-kappaB inhibitor, Bay 11-7082, and hexamethonium, a non-specific nAChR blocker. Hexamethonium 127-140 BCL2 associated X, apoptosis regulator Homo sapiens 23-26 27028622-10 2016 Nicotine increased the Bax/Bcl-2 ratio, which was attenuated by N-acetyl-L-cysteine, the NF-kappaB inhibitor, Bay 11-7082, and hexamethonium, a non-specific nAChR blocker. Hexamethonium 127-140 BCL2 apoptosis regulator Homo sapiens 27-32 27028622-12 2016 While nicotine treatment increased the expression of phosphorylated cdc2 and histone H3, a marker of G2/M phase arrest, hexamethonium and Bay 11-7082 pretreatment reduced their expression. Hexamethonium 120-133 cyclin dependent kinase 1 Homo sapiens 68-72 24504265-7 2014 This increase in rCBF was reduced significantly by the administration of hexamethonium and atropine. Hexamethonium 73-86 CCAAT/enhancer binding protein zeta Rattus norvegicus 17-21 25948261-9 2015 Furthermore, at E12.5 we found evidence for unconventional receptors that were responsive to the nAChR agonists 1-dimethyl-4-phenylpiperazinium and nicotine, but were insensitive to the general nicotinic blocker, hexamethonium. Hexamethonium 213-226 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 97-102 25617597-6 2015 Labeling of lt14a with an Alexa Fluor 488 ester showed that lt14a was bound to the surface of PC12 cells and that this binding was inhibited by pre-application of the nicotinic acetylcholine receptor (nAChR) antagonist tubocurarine chloride (TUB) and the nAChR blocker hexamethonium bromide (HB). Hexamethonium 269-290 cholinergic receptor nicotinic alpha 2 subunit Rattus norvegicus 167-199 25617597-6 2015 Labeling of lt14a with an Alexa Fluor 488 ester showed that lt14a was bound to the surface of PC12 cells and that this binding was inhibited by pre-application of the nicotinic acetylcholine receptor (nAChR) antagonist tubocurarine chloride (TUB) and the nAChR blocker hexamethonium bromide (HB). Hexamethonium 269-290 cholinergic receptor nicotinic alpha 2 subunit Rattus norvegicus 201-206 25617597-6 2015 Labeling of lt14a with an Alexa Fluor 488 ester showed that lt14a was bound to the surface of PC12 cells and that this binding was inhibited by pre-application of the nicotinic acetylcholine receptor (nAChR) antagonist tubocurarine chloride (TUB) and the nAChR blocker hexamethonium bromide (HB). Hexamethonium 292-294 cholinergic receptor nicotinic alpha 2 subunit Rattus norvegicus 167-199 25617597-6 2015 Labeling of lt14a with an Alexa Fluor 488 ester showed that lt14a was bound to the surface of PC12 cells and that this binding was inhibited by pre-application of the nicotinic acetylcholine receptor (nAChR) antagonist tubocurarine chloride (TUB) and the nAChR blocker hexamethonium bromide (HB). Hexamethonium 292-294 cholinergic receptor nicotinic alpha 2 subunit Rattus norvegicus 201-206 25492829-7 2014 In contrast, when pretreated with hexamethonium, a ganglionic blocker, simvastatin and pravastatin groups showed a similar hypertensive response to Ang II, which was smaller than in controls. Hexamethonium 34-47 angiotensinogen Rattus norvegicus 148-154 25010841-7 2014 Furthermore, the decrease in ET-1 gene expression induced by re-feeding was blocked by pre-treatment with hexamethonium and atropine. Hexamethonium 106-119 endothelin 1 Mus musculus 29-33 24886596-8 2014 Behavioral analysis of ART-OE and wildtype mice showed that Artn-induced thermal hyperalgesia can be blocked by mecamylamine or hexamethonium. Hexamethonium 128-141 artemin Mus musculus 60-64 24578344-11 2014 VIP (100 nM) induced longitudinal muscle contraction that was inhibited by TTX (1 muM), PG97-269 (VPAC1 antagonist; 1 muM), and hyoscine (10 muM), but not by hexamethonium (200 muM). Hexamethonium 158-171 VIP peptides Cavia porcellus 0-3 26843857-10 2016 Moreover, the inhibitory effect of AVP (180 pmol) on gastric motility could be blocked completely by both SR49059 (320 pmol) and hexamethonium (8 mumol). Hexamethonium 129-142 arginine vasopressin Rattus norvegicus 35-38 25503516-5 2015 N-acetyl-cysteine (ROS scavenger) or hexamethonium [nicotinic acetylcholine receptor (nAChR) antagonist] attenuated the CSE-induced increase in intracellular ROS, activation of AMPK and NF-kappaB, as well as IL-8 induction, which suggests that nAChRs and ROS are important. Hexamethonium 37-50 cholinergic receptor nicotinic alpha 4 subunit Homo sapiens 52-84 25503516-5 2015 N-acetyl-cysteine (ROS scavenger) or hexamethonium [nicotinic acetylcholine receptor (nAChR) antagonist] attenuated the CSE-induced increase in intracellular ROS, activation of AMPK and NF-kappaB, as well as IL-8 induction, which suggests that nAChRs and ROS are important. Hexamethonium 37-50 cholinergic receptor nicotinic alpha 4 subunit Homo sapiens 86-91 25503516-5 2015 N-acetyl-cysteine (ROS scavenger) or hexamethonium [nicotinic acetylcholine receptor (nAChR) antagonist] attenuated the CSE-induced increase in intracellular ROS, activation of AMPK and NF-kappaB, as well as IL-8 induction, which suggests that nAChRs and ROS are important. Hexamethonium 37-50 protein kinase AMP-activated catalytic subunit alpha 2 Homo sapiens 177-181 25503516-5 2015 N-acetyl-cysteine (ROS scavenger) or hexamethonium [nicotinic acetylcholine receptor (nAChR) antagonist] attenuated the CSE-induced increase in intracellular ROS, activation of AMPK and NF-kappaB, as well as IL-8 induction, which suggests that nAChRs and ROS are important. Hexamethonium 37-50 nuclear factor kappa B subunit 1 Homo sapiens 186-195 25503516-5 2015 N-acetyl-cysteine (ROS scavenger) or hexamethonium [nicotinic acetylcholine receptor (nAChR) antagonist] attenuated the CSE-induced increase in intracellular ROS, activation of AMPK and NF-kappaB, as well as IL-8 induction, which suggests that nAChRs and ROS are important. Hexamethonium 37-50 C-X-C motif chemokine ligand 8 Homo sapiens 208-212 25514605-7 2015 A pretreatment with nicotinic acetylcholine receptor antagonists hexamethonium, mecamylamine, and methyllycaconitine, but not dextrometorphan, canceled the TH-LI nerve reinnervation induced by nicotine. Hexamethonium 65-78 cholinergic receptor nicotinic alpha 2 subunit Rattus norvegicus 20-52 23183626-7 2013 Hexamethonium (10 mg/kg, sc) prevented Ucn 1-induced rise in total ghrelin levels while not altering the hyperglycemic response. Hexamethonium 0-13 ghrelin and obestatin prepropeptide Rattus norvegicus 67-74 23388515-11 2013 After hexamethonium treatment, it was found that the acute hypertension induced by 6-hydroxydopamine lesions was immediately reversed and the acute high rise of catecholamine serum level was significantly attenuated within 3 hours, accompanied by preserved cardiac output and decreased expressions of connexin 43 in the heart and lungs. Hexamethonium 6-19 gap junction protein, alpha 1 Rattus norvegicus 301-312 22635074-5 2012 In a second set of experiments, we demonstrated that the increased expression of myocardial phosphorylated-Akt and endothelial nitric oxide synthase induced by intrathecal morphine was blocked by prior administration of hexamethonium. Hexamethonium 220-233 AKT serine/threonine kinase 1 Homo sapiens 107-110 22902499-5 2012 KEY FINDINGS: Both nAChR and mAChR antagonists (hexamethonium and methacine, respectively), per se, elevated histamine-releasing activity of the HMC-1 and suppressed the MC responses to most of investigated activators (carbachol, compound 48/80, and to a lesser extent aIgG). Hexamethonium 48-61 cholinergic receptor nicotinic alpha 4 subunit Homo sapiens 19-24 23149874-7 2012 Nicotinic acetylcholine receptor (nAChR) blocker hexamethonium, MEK1/2 inhibitor PD98059, p38 MAPK inhibitor SB203580 and NF-kappaB inhibitor PDTC almost completely abolished nicotineinduced CRP expression in mRNA and protein levels in U937 macrophages. Hexamethonium 49-62 cholinergic receptor nicotinic alpha 4 subunit Homo sapiens 0-32 23149874-7 2012 Nicotinic acetylcholine receptor (nAChR) blocker hexamethonium, MEK1/2 inhibitor PD98059, p38 MAPK inhibitor SB203580 and NF-kappaB inhibitor PDTC almost completely abolished nicotineinduced CRP expression in mRNA and protein levels in U937 macrophages. Hexamethonium 49-62 cholinergic receptor nicotinic alpha 4 subunit Homo sapiens 34-39 23149874-8 2012 The further study indicated that hexamethonium, PD98059, and SB203580 significantly inhibited ERK1/2 and p38 MAPK phosphorylation. Hexamethonium 33-46 mitogen-activated protein kinase 3 Homo sapiens 94-100 23149874-8 2012 The further study indicated that hexamethonium, PD98059, and SB203580 significantly inhibited ERK1/2 and p38 MAPK phosphorylation. Hexamethonium 33-46 mitogen-activated protein kinase 1 Homo sapiens 105-108 22635074-5 2012 In a second set of experiments, we demonstrated that the increased expression of myocardial phosphorylated-Akt and endothelial nitric oxide synthase induced by intrathecal morphine was blocked by prior administration of hexamethonium. Hexamethonium 220-233 nitric oxide synthase 3 Homo sapiens 115-148 22127290-6 2012 This response was diminished reversibly by the non-selective nAChR blocker hexamethonium, by the selective alpha7 blocker alpha-bungarotoxin and by the alpha4-containing nAChR blocker erysodine. Hexamethonium 75-88 cholinergic receptor nicotinic beta 1 subunit Rattus norvegicus 61-66 22241831-8 2012 Effects of the highest dose studied were blocked by mecamylamine (general nAChR antagonist) and partially antagonized by hexamethonium (largely peripheral nAChR antagonist). Hexamethonium 121-134 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 155-160 22114134-6 2012 Additionally, the MVR response to hexamethonium was enhanced on days 10 and 13 of ANG II selectively in HS rats. Hexamethonium 34-47 angiogenin Rattus norvegicus 82-85 22114134-7 2012 Compared with LS rats, HR in HS rats was higher during the 2nd wk of ANG II, and its response to hexamethonium was greater on days 7, 10, and 13 of ANG II. Hexamethonium 97-110 angiotensinogen Rattus norvegicus 148-154 22085992-10 2012 The nicotinic-acetylcholine receptor (nAChR) blocker hexamethonium induced a significant inhibition of the [(3)H]dopamine release produced by CC in PC12 cells but the TZ-elicited release of [(3)H]dopamine was 70% hexamethonium-insensitive, suggesting unidentified TZ toxins affecting other regulatory mechanisms of catecholamine secretion. Hexamethonium 53-66 cholinergic receptor nicotinic alpha 2 subunit Rattus norvegicus 4-36 22085992-10 2012 The nicotinic-acetylcholine receptor (nAChR) blocker hexamethonium induced a significant inhibition of the [(3)H]dopamine release produced by CC in PC12 cells but the TZ-elicited release of [(3)H]dopamine was 70% hexamethonium-insensitive, suggesting unidentified TZ toxins affecting other regulatory mechanisms of catecholamine secretion. Hexamethonium 53-66 cholinergic receptor nicotinic alpha 2 subunit Rattus norvegicus 38-43 22085992-10 2012 The nicotinic-acetylcholine receptor (nAChR) blocker hexamethonium induced a significant inhibition of the [(3)H]dopamine release produced by CC in PC12 cells but the TZ-elicited release of [(3)H]dopamine was 70% hexamethonium-insensitive, suggesting unidentified TZ toxins affecting other regulatory mechanisms of catecholamine secretion. Hexamethonium 213-226 cholinergic receptor nicotinic alpha 2 subunit Rattus norvegicus 4-36 22085992-10 2012 The nicotinic-acetylcholine receptor (nAChR) blocker hexamethonium induced a significant inhibition of the [(3)H]dopamine release produced by CC in PC12 cells but the TZ-elicited release of [(3)H]dopamine was 70% hexamethonium-insensitive, suggesting unidentified TZ toxins affecting other regulatory mechanisms of catecholamine secretion. Hexamethonium 213-226 cholinergic receptor nicotinic alpha 2 subunit Rattus norvegicus 38-43 20679729-8 2010 By contrast, inhibition of ganglionic transmission with either hexamethonium or prazosin abolished the difference in blood pressure between Trpm4-/- and wild-type mice. Hexamethonium 63-76 transient receptor potential cation channel, subfamily M, member 4 Mus musculus 140-145 22029733-7 2011 The responses to suncus motilin in the stomach were completely abolished by atropine and tetrodotoxin treatment and significantly suppressed by administration of hexamethonium, verapamil, phentolamine, yohimbine, ondansetron, and naloxone, whereas ritanserin, prazosin, timolol, and FK888 did not affect the action of motilin. Hexamethonium 162-175 motilin Canis lupus familiaris 24-31 21707927-10 2011 ANGII or methoxamine given to hexamethonium-pretreated or untreated rats increased MAP similarly, but produced contrasting effects on erectile responses. Hexamethonium 30-43 angiotensinogen Rattus norvegicus 0-5 21073474-5 2011 UVA irradiation of the eye suppressed the intestinal peristalsis of control, hypophysectomized or iNOS(-/-) C57BL/6J mice by the mechanism that was inhibited by hexamethonium or prazosin plus propranolol. Hexamethonium 161-174 nitric oxide synthase 2, inducible Mus musculus 98-102 20615399-7 2010 In sigmoid circular muscle, neurotensin responses were also enhanced by TTX and hexamethonium, but were attenuated in the presence of mepyramine, MEN10627 and CP99994, suggesting inhibitory neuronal mechanisms and involvement of histamine and tachykinins, respectively; L-NAME and the GABA(B) receptor antagonist, CGP36742, were without effect. Hexamethonium 80-93 neurotensin Homo sapiens 28-39 21393361-7 2011 In addition, hexamethonium produced a greater decrease in blood pressure in Ang II-infused rats. Hexamethonium 13-26 angiotensinogen Rattus norvegicus 76-82 21112947-9 2011 When animals from all studies underwent ganglionic blockade with hexamethonium, there was a smaller reduction in the fall of BP in animals receiving icv AT1R or MR antagonists. Hexamethonium 65-78 angiotensin II receptor, type 1a Rattus norvegicus 153-157 21112947-9 2011 When animals from all studies underwent ganglionic blockade with hexamethonium, there was a smaller reduction in the fall of BP in animals receiving icv AT1R or MR antagonists. Hexamethonium 65-78 nuclear receptor subfamily 3, group C, member 2 Rattus norvegicus 161-163 18651290-14 2008 Hexamethonium, a nonselective antagonist of nicotinic acetylcholine receptors (nAChRs), significantly inhibited nicotine-induced VEGF protein expression (P < 0.01). Hexamethonium 0-13 vascular endothelial growth factor A Oryctolagus cuniculus 129-133 20602018-6 2010 However, hexamethonium + ouabain increased DAP sensitivity to PHE. Hexamethonium 9-22 death-associated protein Rattus norvegicus 43-46 19914944-12 2010 The marked rise in heart rate in response to UCN2 is preserved in sheep undergoing pharmacological ganglionic blockade with hexamethonium. Hexamethonium 124-137 urocortin-2 Ovis aries 45-49 19070647-6 2009 When coapplied with 100microM ACh, HBB concentration-dependently suppressed currents with an IC(50) value of 0.19+/-0.04microM, and was approximately seven-times more potent than the ganglionic blocker, hexamethonium (IC(50)=1.3+/-0.3microM). Hexamethonium 203-216 hemoglobin subunit beta Homo sapiens 35-38 20105082-3 2010 Dihydrobetaerythroidine (antagonist of heteromeric nAChR), and hexamethonium (antagonist of peripheral nAChR), fully antagonized the effect of MDMA. Hexamethonium 63-76 cholinergic receptor nicotinic alpha 4 subunit Homo sapiens 103-108 19749751-6 2009 In the presence of the general nAChR blocker hexamethonium, nociceptive neurons showed nicotine-induced responses that were strongly reduced in TRPA1-deficient mice. Hexamethonium 45-58 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 31-36 19749751-6 2009 In the presence of the general nAChR blocker hexamethonium, nociceptive neurons showed nicotine-induced responses that were strongly reduced in TRPA1-deficient mice. Hexamethonium 45-58 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 144-149 19239625-7 2009 Pretreatment with hexamethonium markedly reduced gastric relaxation induced by secretin (5.6 pmol kg(-1) h(-1)). Hexamethonium 18-31 secretin Rattus norvegicus 79-87 18423439-4 2008 In addition, the corticotropin-releasing factor-induced elevation of noradrenaline release in the hypothalamic paraventricular nucleus and plasma corticosterone were abolished by hexamethonium, a non-selective nicotinic acetylcholine receptor antagonist, at 1.8 micromol/animal, intracerebroventricularly, and alpha-conotoxin MII, a potent alpha(3)beta(2) nicotinic acetylcholine receptor antagonist, at 30 nmol/animal, i.c.v. Hexamethonium 179-192 corticotropin releasing hormone Rattus norvegicus 17-47 18567834-6 2008 The subunit-nonselective nAChR antagonist hexamethonium (100 micromol/kg) and the selective alpha7-subunit antagonist methyllycaconitine (MLA; 3 and 10 micromol/kg) decreased the nicotine-induced tachycardia by 100 and 40%, respectively (maximal effects), suggesting that nAChRs containing the alpha7-subunit account for 40% of the nicotine-induced tachycardia. Hexamethonium 42-55 cholinergic receptor nicotinic beta 1 subunit Rattus norvegicus 25-30 18499160-9 2008 RESULTS: Intravesical lidocaine or ganglionic blockage with hexamethonium prevented substance P induced macrophage migration inhibitory factor release. Hexamethonium 60-73 macrophage migration inhibitory factor Rattus norvegicus 104-142 18423439-4 2008 In addition, the corticotropin-releasing factor-induced elevation of noradrenaline release in the hypothalamic paraventricular nucleus and plasma corticosterone were abolished by hexamethonium, a non-selective nicotinic acetylcholine receptor antagonist, at 1.8 micromol/animal, intracerebroventricularly, and alpha-conotoxin MII, a potent alpha(3)beta(2) nicotinic acetylcholine receptor antagonist, at 30 nmol/animal, i.c.v. Hexamethonium 179-192 cholinergic receptor nicotinic alpha 2 subunit Rattus norvegicus 210-242 18423439-4 2008 In addition, the corticotropin-releasing factor-induced elevation of noradrenaline release in the hypothalamic paraventricular nucleus and plasma corticosterone were abolished by hexamethonium, a non-selective nicotinic acetylcholine receptor antagonist, at 1.8 micromol/animal, intracerebroventricularly, and alpha-conotoxin MII, a potent alpha(3)beta(2) nicotinic acetylcholine receptor antagonist, at 30 nmol/animal, i.c.v. Hexamethonium 179-192 cholinergic receptor nicotinic alpha 2 subunit Rattus norvegicus 356-388 16938493-10 2007 Icv-injection of GLP-1 (3 nmol)-induced acceleration of colonic transit was attenuated by vagotomy, atropine and hexamethonium, but not by guanethidine. Hexamethonium 113-126 glucagon Rattus norvegicus 17-22 18258664-6 2008 The KCl-induced increase in TH expression was partly reduced in the presence of the nicotinic receptor antagonist hexamethonium (100 microm), of noradrenaline (1 microm) and of the alpha(2)-adrenoreceptor agonist clonidine (1 microm). Hexamethonium 114-127 tyrosine hydroxylase Rattus norvegicus 28-30 18079280-9 2008 FTS Ca(2+) responses were inhibited by Omega-conotoxin (70%), hexamethonium (50%), TTX, high Mg(2+)/low Ca(2+) (< or = 100%), or capsaicin (25%). Hexamethonium 62-75 AKT interacting protein Homo sapiens 0-3 18162319-10 2008 600 micromol/kg of CDP-choline, phosphocholine or choline were abolished by pretreatment with the ganglionic nicotinic acetylcholine receptor antagonist hexamethonium (15 mg/kg; i.p. Hexamethonium 153-166 cut-like homeobox 1 Rattus norvegicus 19-22 17727820-4 2007 The classical antagonists, hexamethonium and decamethonium, differentiate between peripheral nAChR subtypes. Hexamethonium 27-40 cholinergic receptor nicotinic beta 1 subunit Rattus norvegicus 93-98 17784838-6 2007 Furthermore, the antiapoptotic effect of nicotine was blocked completely by nicotinic acetylcholine receptor (nAChR) antagonist hexamethonium. Hexamethonium 128-141 cholinergic receptor nicotinic alpha 4 subunit Homo sapiens 76-108 17784838-6 2007 Furthermore, the antiapoptotic effect of nicotine was blocked completely by nicotinic acetylcholine receptor (nAChR) antagonist hexamethonium. Hexamethonium 128-141 cholinergic receptor nicotinic alpha 4 subunit Homo sapiens 110-115 18257750-9 2008 600 mumol/kg of CDP-choline, phosphocholine or choline were abolished by pre-treatment with hexamethonium (15 mg/kg; i.p. Hexamethonium 92-105 cut like homeobox 1 Homo sapiens 16-19 17884041-6 2007 Pretreatment with atropine plus hexamethonium attenuated or blocked pressor response to CDP-choline or phosphocholine, respectively. Hexamethonium 32-45 cut-like homeobox 1 Rattus norvegicus 88-91 17884041-7 2007 Heart rate responses to CDP-choline, phosphocholine and choline were blocked by atropine and reversed by hexamethonium. Hexamethonium 105-118 cut-like homeobox 1 Rattus norvegicus 24-27 17900562-6 2007 Truncal vagotomy, perivagal application of capsaicin and hexamethonium reduced CNP-evoked pancreatic flow and abolished chloride excretion but did not affect protein output. Hexamethonium 57-70 natriuretic peptide C Rattus norvegicus 79-82 17666046-5 2007 Nicotine-induced ERK phosphorylation was inhibited by high concentrations of mecamylamine, however it was not blocked by other broad nicotinic acetylcholine receptor (nAChR) inhibitors (including hexamethonium and chlorisondamine) or nAChR subtype selective inhibitors (such as methyllycaconitine, alpha-bungarotoxin, dihydro-beta-erythroidine, and alpha-conotoxin Au1B). Hexamethonium 196-209 mitogen-activated protein kinase 1 Mus musculus 17-20 17517423-4 2007 Cis-4-aminocrotonic acid (CACA), a specific GABA(C) receptor agonist, induced an inhibitory effect, consisting in the reduction of the amplitude of the spontaneous contractions and muscular relaxation, which was antagonised by TPMPA, GABA(C)-receptor antagonist, TTX or N(omega)-nitro-l-arginine methyl ester (L-NAME), nitric oxide (NO) synthase inhibitor, but not affected by hexamethonium. Hexamethonium 377-390 suppressor of cytokine signaling 6 Mus musculus 0-5 17517423-4 2007 Cis-4-aminocrotonic acid (CACA), a specific GABA(C) receptor agonist, induced an inhibitory effect, consisting in the reduction of the amplitude of the spontaneous contractions and muscular relaxation, which was antagonised by TPMPA, GABA(C)-receptor antagonist, TTX or N(omega)-nitro-l-arginine methyl ester (L-NAME), nitric oxide (NO) synthase inhibitor, but not affected by hexamethonium. Hexamethonium 377-390 gamma-aminobutyric acid (GABA) C receptor, subunit rho 2 Mus musculus 234-250 17286987-5 2007 Hexamethonium, an antagonist of nicotinic acetylcholine receptor (nAChR), inhibited nicotine-induced VEGF release. Hexamethonium 0-13 cholinergic receptor nicotinic alpha 2 subunit Rattus norvegicus 32-64 17286987-5 2007 Hexamethonium, an antagonist of nicotinic acetylcholine receptor (nAChR), inhibited nicotine-induced VEGF release. Hexamethonium 0-13 cholinergic receptor nicotinic alpha 2 subunit Rattus norvegicus 66-71 17286987-5 2007 Hexamethonium, an antagonist of nicotinic acetylcholine receptor (nAChR), inhibited nicotine-induced VEGF release. Hexamethonium 0-13 vascular endothelial growth factor A Rattus norvegicus 101-105 17334538-3 2007 Sympathetic blockade with hexamethonium essentially caused a decrease in total peripheral resistance in hypertensive animals (conscious, 2 days: from (means +/- SEM) 2.47 +/- 0.08 to 2.14 +/- 0.07; conscious, 7 days: from 2.85 +/- 0.13 to 2.07 +/- 0.33; anesthetized, 2 days: from 3.00 +/- 0.09 to 1.83 +/- 0.25 and anesthetized, 7 days: from 3.56 +/- 0.11 to 1.53 +/- 0.10 mmHg mL-1 min-1) with no change in CO in either group. Hexamethonium 26-39 L1 cell adhesion molecule Mus musculus 379-389 17085676-9 2007 However, hexamethonium after previous antagonism of the angiotensin II type 1 (AT(1)) receptors with losartan produced a larger decrease in MAP in the CIH than in the control group (-58 +/- 2 versus -50 +/- 2 mmHg, P = 0.0165). Hexamethonium 9-22 angiotensin II receptor, type 1a Rattus norvegicus 56-84 17141214-8 2007 The present results suggest that subchronic treatment with the nicotinic acetylcholine receptor antagonist hexamethonium reduces a GABA(A)-R mediated counteraction of the nucleus accumbens dopamine response to ethanol. Hexamethonium 107-120 cholinergic receptor nicotinic alpha 2 subunit Rattus norvegicus 63-95 16762378-7 2006 The OXA-induced contraction was significantly inhibited by hexamethonium and SB-334867-A, whereas the nicotine-induced contraction was not inhibited by SB-334867-A. Hexamethonium 59-72 hypocretin Mus musculus 4-7 16762503-8 2006 Both the plasma glucose lowering action and the raised plasma levels of insulin and C-peptide induced by Hon-Chi were also inhibited by 4-diphenylacetoxy-N-methylpiperdine methiodide (4-DAMP), but not affected by the ganglionic nicotinic antagonist, pentolinium or hexamethonium, indicating the mediation of muscarinic M(3) receptors. Hexamethonium 265-278 insulin 2 Rattus norvegicus 84-93 16792571-10 2006 Intracerebellar pretreatment with hexamethonium, a nicotinic receptor (nAChR) antagonist, significantly blocked nicotine-induced attenuation of ethanol ataxia suggesting participation of nAChRs. Hexamethonium 34-47 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 71-76 16469825-4 2006 Pretreatment with atropine or hexamethonium or an acute vagotomy, but not a perivagal application of capsaicin, completely abolished pancreatic protein secretion responses to ghrelin. Hexamethonium 30-43 ghrelin and obestatin prepropeptide Rattus norvegicus 175-182 15680490-9 2005 Ganglion blockade with hexamethonium did not influence CGRP release by RPC but abolished CGRP mediated myocardial PKCepsilon activation. Hexamethonium 23-36 calcitonin-related polypeptide alpha Rattus norvegicus 89-93 16263110-5 2005 CNP response was diminished by atropine and hexamethonium, but it was abolished by vagotomy. Hexamethonium 44-57 natriuretic peptide C Rattus norvegicus 0-3 16520739-3 2006 Stimulation of PAR-2 by trypsin-induced relaxation of carbachol- and KCl-induced contractions in normal rat colonic smooth muscle was completely resolved by tissue pretreatment with apamin, but not by pretreatment with l-NMMA or a cocktail of neuronal blockers (tetrodotoxin, hexamethonium and propranolol). Hexamethonium 276-289 F2R like trypsin receptor 1 Rattus norvegicus 15-20 14714611-3 2003 The insulin-releasing activity of motilin in the fed state was completely abolished by pretreatment with atropine or hexamethonium and was partly inhibited by ondansetron. Hexamethonium 117-130 insulin Canis lupus familiaris 4-11 15576667-6 2005 Prazosin and hexamethonium produced greater decreases in mean AP in AT1a -/- than in AT1a +/+. Hexamethonium 13-26 angiotensin II receptor, type 1a Mus musculus 68-72 15576667-6 2005 Prazosin and hexamethonium produced greater decreases in mean AP in AT1a -/- than in AT1a +/+. Hexamethonium 13-26 angiotensin II receptor, type 1a Mus musculus 85-89 15707012-6 2004 infusion of orphanin FQ (36 microg) also prevented the onset of aconitine-induced arrhythmia, but this effect was completely abolished by hexamethonium. Hexamethonium 138-151 prepronociceptin Rattus norvegicus 12-23 15066018-6 2004 Pretreatment with capsaicin or hexamethonium, combination of both pretreatments or vagotomy reduced HCl-induced c-Fos expression by 54%, 66%, 63% and 68%, respectively. Hexamethonium 31-44 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 112-117 15273750-2 2004 Atropine reduced, while hexamethonium completely abolished the arrhythmogenic effect of endothelin-1 during nitric oxide synthase inhibition. Hexamethonium 24-37 endothelin 1 Mus musculus 88-100 15501701-8 2004 The excitatory response to vasopressin was Tetrodotoxin [TTX]-resistant and was not affected by pre-treatment with phentolamine [10(-5) M], atropine [10(-5) M], and hexamethonium [10(-5) M]. Hexamethonium 165-178 arginine vasopressin Homo sapiens 27-38 14714611-3 2003 The insulin-releasing activity of motilin in the fed state was completely abolished by pretreatment with atropine or hexamethonium and was partly inhibited by ondansetron. Hexamethonium 117-130 motilin Canis lupus familiaris 34-41 15040854-11 2003 Pretreatment with the ganglion blocker hexamethonium and with atropine completely abolished the stimulatory effect of central ghrelin. Hexamethonium 39-52 ghrelin and obestatin prepropeptide Rattus norvegicus 126-133 14573394-5 2003 Like nicotine, the contraction induced by 100 nM urotensin II was inhibited by treatment with atropine, hexamethonium, D-tubocurarine, tetrodotoxin or hemicholinium-3, and enhanced by physostigmine. Hexamethonium 104-117 urotensin 2 Homo sapiens 49-61 12588467-6 2003 Pre-treatment with capsaicin or hexamethonium or a combination of both pre-treatments reduced HCl-induced c-Fos expression by 54, 66 and 63%, respectively. Hexamethonium 32-45 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 106-111 12829438-12 2003 Moreover, in the presence of hexamethonium or Nomega-nitro-l-arginine methyl ester, an inhibitor of NOS, responses caused by mGluR8 agonists were abolished. Hexamethonium 29-42 glutamate receptor, metabotropic 8 Mus musculus 125-131 12898092-4 2003 The nicotinic antagonists HXM (50 microM), methyllycaconitine (MLA, 0.01 microM) and dihydro-beta-erythroidine (DHbetaE, 50 microM) potentiated CA3-evoked field potentials. Hexamethonium 26-29 carbonic anhydrase 3 Rattus norvegicus 144-147 12740863-4 2003 The rank potency order of nAChR antagonists to reduce tetanic peak tension was alpha-bungarotoxin > d-tubocurarine >> mecamylamine > hexamethonium. Hexamethonium 145-158 cholinergic receptor nicotinic beta 1 subunit Rattus norvegicus 26-31 12966717-3 2003 Intracerebroventricular infusion of orphanin FQ was shown to increase cardiac tolerance of arrhythmogenic influence of aconitine, but this effect is completely abolished by hexamethonium administration. Hexamethonium 173-186 prepronociceptin Homo sapiens 36-47 12606764-4 2003 beta 4(-/-) mice had an attenuated bradycardiac response to high frequency (60 pulse/s) vagal stimulation, as well as an increased sensitivity to hexamethonium blockade at low dose (3 mg/kg) and a reduced ileal contractile response to the nicotinic agonists cytisine, dimethylphenylpiperazinium iodide, nicotine (10 mg/kg each), and epibatidine (0.1 mg/kg). Hexamethonium 146-159 basic helix-loop-helix family, member e23 Mus musculus 0-6 12711315-8 2003 Plasma ghrelin levels in hexamethonium-treated animals were greater (P<0.05) than those of atropine-treated animals. Hexamethonium 25-38 appetite-regulating hormone Ovis aries 7-14 12488235-3 2003 The nicotinic agonist 1,1-dimethyl-4-phenylpiperazinium (DMPP) stimulated ANP secretion; the effect was abolished by hexamethonium but doubled by atropine. Hexamethonium 117-130 natriuretic peptide A Rattus norvegicus 74-77 12522097-7 2003 4 The nicotinic ganglionic acetylcholine receptor antagonist hexamethonium (1 microM) and the muscarinic acetylcholine receptor antagonist atropine (1 microM) also decreased the NK(3) receptor agonist-induced J(G) by 67% (n=10) and 71% (n=12), respectively. Hexamethonium 61-74 tachykinin receptor 3 Homo sapiens 178-192 12409836-8 2002 Pretreatment with the ganglion blocker hexamethonium and with atropine completely abolished the stimulatory effect of central Orexin-A. Hexamethonium 39-52 hypocretin neuropeptide precursor Rattus norvegicus 126-134 12508375-6 2003 Hexamethonium (10 micromol x L(-1)) partly blocked the inhibition of oxytocin (1 U x L(-1)) on the contractile frenquency of CM. Hexamethonium 0-13 oxytocin Oryctolagus cuniculus 69-77 12047040-6 2002 Successive administration of V1A after ganglionic blockade with hexamethonium bromide (C6; 25 mg/kg), however, significantly attenuated renal, mesenteric and hindquarter resistances in BHR but not in NCR. Hexamethonium 64-85 arginine vasopressin receptor 1A Rattus norvegicus 29-32 12595959-0 2003 Inhibitory effects of atropine and hexamethonium on the angiotensin II-induced contractions of rat anococcygeus smooth muscles. Hexamethonium 35-48 angiotensinogen Rattus norvegicus 56-70 12595959-6 2003 Additionally, hexamethonium inhibited the contraction induced by Ang II in a concentration-dependent fashion with a decrease in E(max). Hexamethonium 14-27 angiotensinogen Rattus norvegicus 65-71 12595959-7 2003 Association of atropine and hexamethonium produced Ang II-induced curves with rightward shifts from the control curve with a decrease in E(max). Hexamethonium 28-41 angiotensinogen Rattus norvegicus 51-57 11413111-8 2001 Pretreatment with hexamethonium (low toxin concentration; acute denervation) attenuated the effect of toxin A on morphology, luminal MPO activity, and number of RBCs. Hexamethonium 18-31 myeloperoxidase Rattus norvegicus 133-136 11447037-4 2001 Hexamethonium (20 mg/kg) also prevented 3-h cold exposure-induced myenteric Fos expression by 76-80%, whereas atropine or bretylium had no effect. Hexamethonium 0-13 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 76-79 11038246-2 2000 Nicotine-induced (0.1 microM) increases in DBI mRNA expression were abolished by hexamethonium, a nicotinic acetylcholine (nACh) receptor antagonist. Hexamethonium 81-94 diazepam binding inhibitor Mus musculus 43-46 28095236-8 2001 Pressor responses to Ang II were not altered by propranolol, phentolamine or atropine, but were enhanced by hexamethonium. Hexamethonium 108-121 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 21-27 11123707-9 2000 Motilin release in response to PGE2 was significantly increased by pretreatment with hexamethonium. Hexamethonium 85-98 motilin Canis lupus familiaris 0-7 11292608-4 2001 Hexamethonium (20 mg/kg sc) prevented Fos expression by 90%, whereas atropine (2 mg/kg sc) had no effect. Hexamethonium 0-13 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 38-41 11223191-6 2001 Hexamethonium decreased by 50% the post BNx increase in prorenin but not active renin. Hexamethonium 0-13 renin Rattus norvegicus 59-64 11731102-3 2001 In contrast, EPSPs were abolished by the nicotinic acetylcholine receptor antagonists, hexamethonium and mecamylamine. Hexamethonium 87-100 cholinergic receptor nicotinic alpha 2 subunit Rattus norvegicus 41-73 10811733-3 2000 The P2X purinoceptor blocker, suramin (50 microM) or a nicotinic ACh receptor (nAChR) blocker (hexamethonium, 100 microM; mecamylamine, 1 microM) only partially inhibited these responses, but together, blocked almost all activity. Hexamethonium 95-108 cholinergic receptor nicotinic beta 1 subunit Rattus norvegicus 79-84 10974664-4 2000 The VIP/PACAP-elicited secretion was diminished in the presence of the VIP receptor antagonist, VIP 6-28, but was unaffected by the PACAP receptor antagonist, PACAP 6-27, or the cholinergic antagonists, hexamethonium and atropine. Hexamethonium 203-216 vasoactive intestinal peptide Gallus gallus 4-7 10898747-4 2000 The PAF-induced contractions were not significantly reduced by TTX, atropine, or hexamethonium but were significantly inhibited with the PAF receptor antagonists ginkolide B and CV-3988. Hexamethonium 81-94 PCNA clamp associated factor Homo sapiens 4-7 10854732-5 2000 These effects were diminished by prior administration of hexamethonium (nACh-R blocker) within the commissural subnucleus of the nTS. Hexamethonium 57-70 neurotensin/neuromedin N Mustela putorius furo 129-132 10409218-4 1999 Atropine and hexamethonium partially decreased c-fos expression (banding vs. banding + atropine/hexamethonium: 700 +/- 67% vs. 400 +/- 67%, P < 0.05). Hexamethonium 13-26 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 47-52 10702597-0 2000 Intravenous infusion of hexamethonium and atropine but not propranolol diminishes apolipoprotein A-IV gene expression in rat ileum. Hexamethonium 24-37 apolipoprotein A4 Rattus norvegicus 82-101 10702597-3 2000 Apo A-IV mRNA levels in the ileum were significantly lower in hexamethonium- or atropine-infused rats than in saline- (control) or propranolol-infused rats. Hexamethonium 62-75 apolipoprotein A4 Rattus norvegicus 0-8 10702597-5 2000 The lower mRNA levels of apo A-IV in the ileum of hexamethonium-infused rats were observed even in bile-drained rats, indicating that the lower expression was not due to any changes in bile availability. Hexamethonium 50-63 apolipoprotein A4 Rattus norvegicus 25-33 10704720-4 2000 The effect of peptide YY was blocked or strongly decreased by tetrodotoxin, hexamethonium, idazoxan, haloperidol, and the sigma antagonist BMY 14, 802 in both the colon and jejunum. Hexamethonium 76-89 peptide YY Rattus norvegicus 14-24 10592302-3 1999 Intraperitoneal administration of the ganglion blocker hexamethonium (20 mg/kg) or the beta-adrenergic antagonist propranolol (5 mg/kg) suppressed the CGRP-induced increases in VO(2), HR, T(co), and T(IBAT). Hexamethonium 55-68 calcitonin-related polypeptide alpha Rattus norvegicus 151-155 10592302-3 1999 Intraperitoneal administration of the ganglion blocker hexamethonium (20 mg/kg) or the beta-adrenergic antagonist propranolol (5 mg/kg) suppressed the CGRP-induced increases in VO(2), HR, T(co), and T(IBAT). Hexamethonium 55-68 solute carrier family 10 member 2 Rattus norvegicus 201-205 10444454-7 1999 CRH-induced changes in ion secretion were abolished by alpha-helical CRH-(9-41), hexamethonium, atropine, or doxantrazole. Hexamethonium 81-94 corticotropin releasing hormone Rattus norvegicus 0-3 10444454-8 1999 CRH-stimulated conductance was significantly inhibited by alpha-helical CRH-(9-41), hexamethonium, bretylium, or doxantrazole. Hexamethonium 84-97 corticotropin releasing hormone Rattus norvegicus 0-3 10409218-4 1999 Atropine and hexamethonium partially decreased c-fos expression (banding vs. banding + atropine/hexamethonium: 700 +/- 67% vs. 400 +/- 67%, P < 0.05). Hexamethonium 96-109 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 47-52 10363713-11 1999 Distension elicited hexamethonium-resistant pCREB immunoreactivity in calbindin-immunoreactive neurons in each plexus; however, in preparations stimulated in the presence of omega-CTx GVIA, pCREB immunoreactivity was found only in calbindin-immunoreactive neurons in the submucosal plexus and not in myenteric ganglia. Hexamethonium 20-33 calbindin 1 Rattus norvegicus 70-79 10386968-5 1999 Also absent was an effect by DMPP on the rate of degradation of TH protein because pulse-chase analysis estimated a half-life for TH of 26 +/- 5 h in DMPP-treated cells, a value that was (a) essentially the same as that estimated in control cells (29 +/- 3 h), (b) within the same range as that estimated by approach to steady state (t(1/2) = 19 +/- 4 h), which measured the decline of TH protein content from the DMPP-induced steady-state level back to the basal value during deinduction with the nicotinic antagonist hexamethonium, and (c) consistent with the time course of accumulation of TH protein to a new steady-state level in response to DMPP. Hexamethonium 519-532 tyrosine hydroxylase Bos taurus 64-66 10363713-11 1999 Distension elicited hexamethonium-resistant pCREB immunoreactivity in calbindin-immunoreactive neurons in each plexus; however, in preparations stimulated in the presence of omega-CTx GVIA, pCREB immunoreactivity was found only in calbindin-immunoreactive neurons in the submucosal plexus and not in myenteric ganglia. Hexamethonium 20-33 calbindin 1 Rattus norvegicus 231-240 9915830-10 1999 Peptide nicotinic antagonists (catestatins, substance P) were far more potent inhibitors of both secretion (p = 0.019) and desensitization (p = 0.005) than nonpeptide antagonists (trimethaphan, hexamethonium, procaine, phencyclidine, cocaine, or clonidine), and the peptides displayed enhanced selectivity to block desensitization versus secretion (p = 0.003). Hexamethonium 194-207 tachykinin precursor 1 Homo sapiens 44-55 9869543-13 1998 ET-1 in the hexamethonium group (n = 2) rose from 2.21 +/- .14 to 11.5 +/- 2.1 pg/ml at 2 hours, and in the spinal group (n = 7) from 2.04 +/- 0.77 to 6.85 +/- 3.9 pg/mL at 45 minutes. Hexamethonium 12-25 endothelin-1 Sus scrofa 0-4 9657354-8 1998 Moreover, inhibition of gastrointestinal motor activity by GLP-1 was blocked by previous infusion of hexamethonium (10 mg/kg) (n = 4). Hexamethonium 101-114 glucagon Rattus norvegicus 59-64 9756504-7 1998 A single injection of TTX, atropine, or hexamethonium reduced the luminal release of 5-HT, whereas a single injection of VIP-(10-28) stimulated the luminal release of 5-HT and this effect was antagonized by atropine, hexamethonium, or TTX. Hexamethonium 217-230 vasoactive intestinal peptide Rattus norvegicus 121-124 9568379-8 1998 Ephedrine, propranolol and phenothiazines including trifluoparazine (TPZ) caused non-competitive inhibition, while hexamethonium caused an uncompetitive inhibition of AChE activity. Hexamethonium 115-128 acetylcholinesterase (Cartwright blood group) Homo sapiens 167-171 9526051-5 1998 Furthermore, this pressor effect of parathyroid hormone-related protein was also abolished after pretreatment by intravenous administration of either hexamethonium bromide or doxazosin mesylate. Hexamethonium 150-171 parathyroid hormone-like hormone Rattus norvegicus 36-71 9458777-5 1998 Exogenous motilin (0.01-0.3 microgram/kg) dose dependently stimulated insulin release, which was abolished by atropine, hexamethonium, ondansetron, and truncal vagotomy. Hexamethonium 120-133 insulin Canis lupus familiaris 70-77 9568379-0 1998 Effects of hexamethonium, phenothiazines, propranolol and ephedrine on acetylcholinesterase carbamylation by physostigmine, aldicarb and carbaryl: interaction between the active site and the functionally distinct peripheral sites in acetylcholinesterase. Hexamethonium 11-24 acetylcholinesterase (Cartwright blood group) Homo sapiens 71-91 9495824-1 1998 To extend our knowledge of the pharmacological profile of human alpha4beta2 neuronal nicotinic receptors, we investigated the action of hexamethonium on the major brain human nicotinic acetylcholine receptor (nAChR) stably expressed in human embryonic kidney 293 cells. Hexamethonium 136-149 cholinergic receptor nicotinic alpha 4 subunit Homo sapiens 175-207 9495824-1 1998 To extend our knowledge of the pharmacological profile of human alpha4beta2 neuronal nicotinic receptors, we investigated the action of hexamethonium on the major brain human nicotinic acetylcholine receptor (nAChR) stably expressed in human embryonic kidney 293 cells. Hexamethonium 136-149 cholinergic receptor nicotinic alpha 4 subunit Homo sapiens 209-214 9568379-12 1998 Hexamethonium protected AChE from inhibition by carbamates and decreased the fluorescence intensity of the physostigmine-inhibited AChE. Hexamethonium 0-13 acetylcholinesterase (Cartwright blood group) Homo sapiens 24-28 9568379-12 1998 Hexamethonium protected AChE from inhibition by carbamates and decreased the fluorescence intensity of the physostigmine-inhibited AChE. Hexamethonium 0-13 acetylcholinesterase (Cartwright blood group) Homo sapiens 131-135 9502051-0 1997 Evaluation of the nature of camel retinal acetylcholinesterase: inhibition by hexamethonium. Hexamethonium 78-91 acetylcholinesterase Camelus bactrianus 42-62 9583573-10 1998 The ganglionic blocking agent, hexamethonium, which blocks autonomic but not afferent pathways to the LUT, decreased c-fos expression by 50%. Hexamethonium 31-44 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 117-122 9502051-1 1997 Acetylcholinesterase (AChE, EC 3.1.1.7) has been demonstrated in retinas of several species, however, the nature of the interaction of AChE with specific inhibitors are very limited in the literature and the mode of inhibition of camel retinal AChE by hexamethonium has been studied. Hexamethonium 252-265 acetylcholinesterase Camelus bactrianus 0-20 9502051-1 1997 Acetylcholinesterase (AChE, EC 3.1.1.7) has been demonstrated in retinas of several species, however, the nature of the interaction of AChE with specific inhibitors are very limited in the literature and the mode of inhibition of camel retinal AChE by hexamethonium has been studied. Hexamethonium 252-265 acetylcholinesterase Camelus bactrianus 22-26 9502051-1 1997 Acetylcholinesterase (AChE, EC 3.1.1.7) has been demonstrated in retinas of several species, however, the nature of the interaction of AChE with specific inhibitors are very limited in the literature and the mode of inhibition of camel retinal AChE by hexamethonium has been studied. Hexamethonium 252-265 acetylcholinesterase Camelus bactrianus 135-139 9502051-1 1997 Acetylcholinesterase (AChE, EC 3.1.1.7) has been demonstrated in retinas of several species, however, the nature of the interaction of AChE with specific inhibitors are very limited in the literature and the mode of inhibition of camel retinal AChE by hexamethonium has been studied. Hexamethonium 252-265 acetylcholinesterase Camelus bactrianus 135-139 9502051-2 1997 Hexamethonium reversibly inhibited AChE in a concentration dependent manner, the IC50 value being c. 2.52 mM. Hexamethonium 0-13 acetylcholinesterase Camelus bactrianus 35-39 9335407-5 1997 The pressor and bradycardic effects evoked by microinjection of ET-1 into the NTS could be blocked by local pretreatment with PD147953 and completely eliminated by intravenous pretreatment with the ganglionic blocker hexamethonium. Hexamethonium 217-230 endothelin 1 Rattus norvegicus 64-68 9350974-9 1997 Pancreatic VIP release during VNS was not affected by atropine, whereas ganglionic blockade with hexamethonium nearly abolished the VIP response to VNS (p<0.005 vs control), suggesting that VIP is a postganglionic neurotransmitter in the dog pancreas. Hexamethonium 97-110 vasoactive intestinal peptide Canis lupus familiaris 132-135 9350974-9 1997 Pancreatic VIP release during VNS was not affected by atropine, whereas ganglionic blockade with hexamethonium nearly abolished the VIP response to VNS (p<0.005 vs control), suggesting that VIP is a postganglionic neurotransmitter in the dog pancreas. Hexamethonium 97-110 vasoactive intestinal peptide Canis lupus familiaris 132-135 9311665-6 1997 The inhibitory effect of peptide YY was suppressed, or strongly and significantly reduced, by tetrodotoxin, hexamethonium, lidocaine, idazoxan and BMY14,802 (51-(4-fluorophenyl)-4-(-4-(5-fluoro-2pyrimidinyl)-1-piperazinyl)- 1-butanol), whereas devazepide and L-NAME (L-omega-N-arginine methyl ester) had no effect. Hexamethonium 108-121 peptide YY Rattus norvegicus 25-35 9277467-5 1997 In contrast, administration of the nicotinic receptor blocker hexamethonium bromide abolished both the depressor and the bradycardic responses elicited by stimulation of the hDB. Hexamethonium 62-83 integrator complex subunit 6 Homo sapiens 174-177 9359598-5 1997 - 60 mV), ACh induced a hexamethonium-sensitive, inward current (IACh), mimicked by nicotine application, suggesting the presence of neuronal nicotinic acetylcholine receptors (nAChR). Hexamethonium 24-37 cholinergic receptor nicotinic beta 1 subunit Rattus norvegicus 142-175 9359598-5 1997 - 60 mV), ACh induced a hexamethonium-sensitive, inward current (IACh), mimicked by nicotine application, suggesting the presence of neuronal nicotinic acetylcholine receptors (nAChR). Hexamethonium 24-37 cholinergic receptor nicotinic beta 1 subunit Rattus norvegicus 177-182 9277431-4 1997 Distension-induced Fos expression was blocked by omega-conotoxin and significantly reduced by hexamethonium, indicating that neurons expressing Fos immunoreactivity were activated synaptically. Hexamethonium 94-107 proto-oncogene c-Fos Cavia porcellus 19-22 9277431-4 1997 Distension-induced Fos expression was blocked by omega-conotoxin and significantly reduced by hexamethonium, indicating that neurons expressing Fos immunoreactivity were activated synaptically. Hexamethonium 94-107 proto-oncogene c-Fos Cavia porcellus 144-147 9299636-6 1997 Atropine or hexamethonium significantly inhibited L-NNA-induced phase III-like contractions and the increase in motilin level. Hexamethonium 12-25 motilin Canis lupus familiaris 112-119 9299636-7 1997 Atropine or hexamethonium significantly inhibited L-NNA-induced phase III-like contractions and the increase in motilin level. Hexamethonium 12-25 motilin Canis lupus familiaris 112-119 9044380-7 1997 The nicotinic acetylcholine receptor antagonists (n-bungarotoxin > mecamylamine > (+)-tubocurarine > hexamethonium > alpha-bungarotoxin = dihydro-beta-erythroidine) and tetrodotoxin antagonized the effect of dimethylphenylpiperazinium to release [3H]noradrenaline. Hexamethonium 110-123 cholinergic receptor nicotinic alpha 2 subunit Rattus norvegicus 4-36 9049141-3 1997 Postprandial PYY release was suppressed or strongly decreased by caecocolonectomy, truncal vagotomy, tetrodotoxin, hexamethonium, sensory denervation by perivagal capsaicin, and by the NO-synthase inhibitor L-N-arginine methyl ester, while atropine, adrenergic blockers, antagonists of type-A or type-B cholecystokinin (CCK) receptors or bombesin receptors had no effect. Hexamethonium 115-128 peptide YY Rattus norvegicus 13-16 8859008-14 1996 Hexamethonium or L-NNA (but not atropine) reduced VIP release; CCK8 still enhanced it. Hexamethonium 0-13 vasoactive intestinal peptide Canis lupus familiaris 50-53 8944704-6 1996 Pretreatment of rats with the CRF antagonist alpha-helical-CRF9-41, hexamethonium, atropine, or bretylium, or the mast cell stabilizer lodoxamide inhibited stress-induced release of RMCP II, PGE2, and mucin, whereas indomethacin prevented mucin release but not mast cell degranulation. Hexamethonium 68-81 mast cell protease 2 Rattus norvegicus 182-189 8942723-7 1996 In vivo, exogenous p-motilin stimulated endogenous c-motilin release and gastric and duodenal phase III-like contractions; this motilin-induced motilin release was inhibited by atropine, hexamethonium, and a 5-hydroxy-tryptamine 3 receptor antagonist. Hexamethonium 187-200 motilin Canis lupus familiaris 21-28 8968331-7 1996 The vasoactive intestinal peptide (VIP) receptor antagonist, VIP-10-28, and the muscarinic antagonist, atropine, individually reduced and together abolished the response to carbacyclin, whereas the nicotinic blocker, hexamethonium, reduced the carbacyclin response by 75%. Hexamethonium 217-230 vasoactive intestinal peptide Homo sapiens 35-38 8901671-9 1996 Hexamethonium (20 mg/kg IV) did not alter protection by 15-minute CAO, but it abolished protection by 15-minute MAO. Hexamethonium 0-13 monoamine oxidase A Rattus norvegicus 112-115 8799571-5 1996 Ascending excitatory reflexes evoked by either distension from the serosal side or compression of the mucosa were depressed by 55% and 85%, respectively, in the presence of hexamethonium (200 microM) and by 30% and 45%, respectively, by a desensitizing concentration of the selective NK3 receptor agonist, senktide (1 microM), in the chamber in which reflexes were initiated. Hexamethonium 173-186 neuromedin-K receptor Cavia porcellus 284-296 8584419-10 1995 Hexamethonium suppressed PYY release induced by the intraduodenal meal, but did not change PYY release induced by glucose or oleic acid in the colon. Hexamethonium 0-13 peptide YY Rattus norvegicus 25-28 8638720-4 1996 Sulfated CCK-8 (S-CCK-8) and nonsulfated CCK-8 initiated or increased ongoing fast excitatory postsynaptic potential (fEPSP) activity, an effect antagonized by hexamethonium. Hexamethonium 160-173 cholecystokinin Homo sapiens 9-12 8637413-6 1996 Hexamethonium only induced a significant decrease in the number of defecations (ND) induced by CCK-8s. Hexamethonium 0-13 cholecystokinin Gallus gallus 95-98 8605958-1 1995 In whole segments of rabbit distal colon with mucosa removed, descending reflex relaxations of the circular muscle (descending inhibition) elicited by inflating (0.1-1 ml) an intraluminal balloon, were partially antagonized by 100 microM hexamethonium and the 5-HT3 receptor antagonist, ondansetron (3 microM), and abolished by 1 microM tetrodotoxin. Hexamethonium 238-251 5-hydroxytryptamine receptor 3A Oryctolagus cuniculus 260-274 7574008-6 1995 Hexamethonium is known to be a weak antagonist at the postsynaptic nicotinic acetylcholine receptor but a potent antagonist at the presynaptic nicotinic receptor. Hexamethonium 0-13 cholinergic receptor nicotinic alpha 2 subunit Rattus norvegicus 67-99 8568687-4 1995 Refeeding of fasted rats induced a transient increase in c-fos mRNA abundance in gastric corpus and antrum that was sixfold within 15 min and declined within 4 h. The response was not mediated by gastrinergic or muscarinic cholinergic mechanisms; it was reduced but not abolished by hexamethonium. Hexamethonium 283-296 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 57-62 7924732-6 1994 The HCO3- secretion during a single intravenous infusion of VIP (12 nmol/kg/hr), 13.9 +/- 4.2 mumol/cm/hr, was unchanged by atropine, reduced to 10.0 +/- 3.5 mumol/cm/hr by hexamethonium, and augmented to 18.9 +/- 4.7 mumol/cm/hr by indomethacin. Hexamethonium 173-186 vasoactive intestinal peptide Rattus norvegicus 60-63 7602539-12 1995 Hexamethonium abolished vagal-stimulated NO production and VIP release. Hexamethonium 0-13 vasoactive intestinal peptide Rattus norvegicus 59-62 7616447-4 1995 These effects of NPFF were also observed, although attenuated, in catecholamine-depleted rats and in rats pretreated with a ganglionic blocking agent, hexamethonium (10 mg/kg, i.v.). Hexamethonium 151-164 neuropeptide FF-amide peptide precursor Rattus norvegicus 17-21 8779278-2 1995 Conformational and geometrical properties of the hexamethylenebis(trimethylammonium) (CH3)3N+-(CH2)6)-N+(CH3)3 (hexamethonium) and its derivatives with various degree of conformational flexibility of interonion chain having disulfide or two dimethylsilane groups or difluoromethylene chain instead of cholinesterase reversible inhibitors have been determined using molecular mechanics methods. Hexamethonium 112-125 butyrylcholinesterase Homo sapiens 301-315 7611400-7 1995 Pretreatment with hexamethonium (10 mg/kg) markedly reduced gastric motor response to secretin (5.6 pmol.kg-1.h-1). Hexamethonium 18-31 secretin Rattus norvegicus 86-94 7539845-10 1995 In line with this it was shown that the SP-evoked release of VIP was also significantly diminished by hexamethonium. Hexamethonium 102-115 tachykinin precursor 1 Homo sapiens 40-42 7539845-10 1995 In line with this it was shown that the SP-evoked release of VIP was also significantly diminished by hexamethonium. Hexamethonium 102-115 vasoactive intestinal peptide Homo sapiens 61-64 7977833-5 1994 The increases in heart rate and lymph VIP output were blocked by hexamethonium. Hexamethonium 65-78 vasoactive intestinal peptide Canis lupus familiaris 38-41 7924732-8 1994 HCl-induced increases in luminal outputs of VIP, substance P, and neurokinin A (the two latter with unknown roles) were differentially affected by atropine, hexamethonium, and indomethacin, indicating that the acid challenge released the peptides through controlled mechanisms. Hexamethonium 157-170 vasoactive intestinal peptide Rattus norvegicus 44-47 7915699-4 1994 RESULTS: Lidocaine, hexamethonium, and capsaicin, but not atropine, inhibited toxin A-mediated secretion and MPO activity, but only capsaicin reduced mannitol permeability. Hexamethonium 20-33 myeloperoxidase Rattus norvegicus 109-112 7959408-6 1994 The potentiation of the acid secretory response to CCK-8 by the CCKA antagonist was completely blocked by vagotomy or atropine, as well as hexamethonium. Hexamethonium 139-152 cholecystokinin Rattus norvegicus 51-54 8113980-8 1994 Hexamethonium and atropine abolished tonic VIP output, leaving intact motility responses to PL017 and DPDPE. Hexamethonium 0-13 vasoactive intestinal peptide Canis lupus familiaris 43-46 8089398-2 1994 In blood-perfused ileum, ACh (2-200 nmol/min) produced a dose-dependent increase in venous VIP output, which was slightly reduced by hexamethonium (10 nmol/min) and blocked by hexamethonium and atropine (10 nmol/min) in combination. Hexamethonium 133-146 vasoactive intestinal peptide Canis lupus familiaris 91-94 8089398-2 1994 In blood-perfused ileum, ACh (2-200 nmol/min) produced a dose-dependent increase in venous VIP output, which was slightly reduced by hexamethonium (10 nmol/min) and blocked by hexamethonium and atropine (10 nmol/min) in combination. Hexamethonium 176-189 vasoactive intestinal peptide Canis lupus familiaris 91-94 8089398-4 1994 ACh-induced VIP output was decreased slightly by hexamethonium (0.1 mM), and blocked by atropine (0.1 mM) or pirenzepine (0.1 mM). Hexamethonium 49-62 vasoactive intestinal peptide Canis lupus familiaris 12-15 8089398-5 1994 Dimethylphenylpiperazinium (0.1 mM) also caused a small increase in VIP output sensitive to hexamethonium in the ileal tissues containing either the submucous or myenteric plexus. Hexamethonium 92-105 vasoactive intestinal peptide Canis lupus familiaris 68-71 7524066-5 1994 Amylase release in response to submaximal concentrations of GRP were significantly inhibited by tetrodotoxin (78 +/- 5% of control) or hexamethonium (71 +/- 5% of control). Hexamethonium 135-148 gastrin releasing peptide Rattus norvegicus 60-63 7512633-4 1994 Selective nicotinic and muscarinic antagonists (hexamethonium and atropine) each partially reduce carbachol-stimulated increases in PNMT mRNA while a combination of both eliminates > 90% of the carbachol response, thus indicating that separable nicotinic and muscarinic components contribute to the cholinergic increase in PNMT mRNA. Hexamethonium 48-61 phenylethanolamine N-methyltransferase Bos taurus 132-136 7512633-4 1994 Selective nicotinic and muscarinic antagonists (hexamethonium and atropine) each partially reduce carbachol-stimulated increases in PNMT mRNA while a combination of both eliminates > 90% of the carbachol response, thus indicating that separable nicotinic and muscarinic components contribute to the cholinergic increase in PNMT mRNA. Hexamethonium 48-61 phenylethanolamine N-methyltransferase Bos taurus 326-330 7913213-4 1994 Hexamethonium (100 microM) completely abolished the nicotine-induced increase in DBI mRNA expression. Hexamethonium 0-13 diazepam binding inhibitor, acyl-CoA binding protein Homo sapiens 81-84 18475595-4 1994 Neurogenic pathways were also involved since pretreatment of ileum with hexamethonium, hemicholinium or tetrodotoxin impaired the contractile effect of interferon gamma. Hexamethonium 72-85 interferon gamma Rattus norvegicus 152-168 8304456-8 1994 Atropine reduced and hexamethonium nearly abolished VIP output. Hexamethonium 21-34 vasoactive intestinal peptide Canis lupus familiaris 52-55 8128898-8 1993 On the other hand, the ODC activity of control segments were decreased by hexamethonium or atropine. Hexamethonium 74-87 ornithine decarboxylase 1 Rattus norvegicus 23-26 8278624-3 1993 Atropine, hexamethonium and atropine plus hexamethonium treatment blocked food-induced release of PYY significantly. Hexamethonium 10-23 peptide YY Canis lupus familiaris 98-101 8278624-3 1993 Atropine, hexamethonium and atropine plus hexamethonium treatment blocked food-induced release of PYY significantly. Hexamethonium 42-55 peptide YY Canis lupus familiaris 98-101 7902011-6 1993 Hexamethonium partially blocked gastric inhibition induced by CCK. Hexamethonium 0-13 cholecystokinin Gallus gallus 62-65 8278624-4 1993 Integrated release of PYY in response to food alone and in combination with atropine, hexamethonium and atropine plus hexamethonium were 8.8 +/- 2.2, -1.1 +/- 2.3, -2.7 +/- 2.2 and -3.2 +/- 3.1 (ng (0-150) min/ml), respectively. Hexamethonium 86-99 peptide YY Canis lupus familiaris 22-25 7511424-3 1993 The ganglionic nicotine antagonist hexamethonium promoted a partial reversal of the inhibitory effect of nicotine on basal or hCG-stimulated T secretion. Hexamethonium 35-48 hypertrichosis 2 (generalised, congenital) Homo sapiens 126-129 8134298-4 1993 A combination of atropine and hexamethonium eliminated the PYY-induced decrement in VIP output and left motor excitation unchanged. Hexamethonium 30-43 peptide YY Canis lupus familiaris 59-62 8134298-4 1993 A combination of atropine and hexamethonium eliminated the PYY-induced decrement in VIP output and left motor excitation unchanged. Hexamethonium 30-43 vasoactive intestinal peptide Canis lupus familiaris 84-87 8335198-6 1993 Atropine, hexamethonium, ICS205-930, BRL43694, phentolamine, yohimbine, and propranolol significantly inhibited motilin-induced contractions. Hexamethonium 10-23 motilin Canis lupus familiaris 112-119 8143235-7 1993 In the presence of hexamethonium, a nicotinic antagonist, PP (i.v.) Hexamethonium 19-32 pancreatic polypeptide Rattus norvegicus 58-60 8099499-1 1993 Influence of inorganic salts on the interaction of cobra venom acetylcholinesterase (EC 3.1.1.7) with hexamethonium and gallamine has been studied. Hexamethonium 102-115 acetylcholinesterase (Cartwright blood group) Homo sapiens 63-83 8100836-5 1993 Pretreatment with atropine or hexamethonium completely abolished pancreatic protein response to low doses of CCK-8 (10-40 pmol/kg per h) but had only partial effect on doses > 40 pmol/kg per h. Bilateral vagotomy also abolished the pancreatic responses to low doses of CCK-8. Hexamethonium 30-43 cholecystokinin Rattus norvegicus 109-112 8100836-5 1993 Pretreatment with atropine or hexamethonium completely abolished pancreatic protein response to low doses of CCK-8 (10-40 pmol/kg per h) but had only partial effect on doses > 40 pmol/kg per h. Bilateral vagotomy also abolished the pancreatic responses to low doses of CCK-8. Hexamethonium 30-43 cholecystokinin Rattus norvegicus 272-275 8099499-3 1993 The ZL psi+Z values for the complex formation between native acetylcholinesterase and hexamethonium (ZL = +2) or gallamine (ZL = +3) were in quantitative agreement with those predicted by the theory making use of psi+1 = 0.50 found earlier from the influence of salts upon the hydrolysis of acetylcholine by the enzyme. Hexamethonium 86-99 acetylcholinesterase (Cartwright blood group) Homo sapiens 61-81 8104355-5 1993 Intravenous administration of hexamethonium significantly stimulated hydroelectrolyte secretion (from 6.99 to 15.15 microliters/min) and the plasma levels of VIP (from 4.8 to 7.3 fmol/ml) and reduced the protein output (from 61.47 to 30.75 micrograms/min) and the plasma levels of CCK (from 14.56 to 6.25 fmol/ml) in the intraduodenally perfused group. Hexamethonium 30-43 VIP peptides Oryctolagus cuniculus 158-161 8366251-8 1993 The increased responses after hexamethonium administration were augmented probably because of the enhanced release of other neuropeptides like SP and CGRP especially at 10 Hz and 20 Hz stimulation. Hexamethonium 30-43 calcitonin-related polypeptide alpha Rattus norvegicus 150-154 8104355-5 1993 Intravenous administration of hexamethonium significantly stimulated hydroelectrolyte secretion (from 6.99 to 15.15 microliters/min) and the plasma levels of VIP (from 4.8 to 7.3 fmol/ml) and reduced the protein output (from 61.47 to 30.75 micrograms/min) and the plasma levels of CCK (from 14.56 to 6.25 fmol/ml) in the intraduodenally perfused group. Hexamethonium 30-43 cholecystokinin Oryctolagus cuniculus 281-284 8097875-6 1993 Atropine and hexamethonium suppressed the stimulatory effect of neurotensin on volume, bicarbonate, and total protein output (p < 0.01). Hexamethonium 13-26 neurotensin Rattus norvegicus 64-75 7694432-3 1993 Pretreatment of the animals with hexamethonium significantly reduced GAL- and GHRH-induced GH secretion, but UK 14304-induced GH release was not affected. Hexamethonium 33-46 galanin and GMAP prepropeptide Rattus norvegicus 69-72 7694432-3 1993 Pretreatment of the animals with hexamethonium significantly reduced GAL- and GHRH-induced GH secretion, but UK 14304-induced GH release was not affected. Hexamethonium 33-46 growth hormone releasing hormone Rattus norvegicus 78-82 7694432-3 1993 Pretreatment of the animals with hexamethonium significantly reduced GAL- and GHRH-induced GH secretion, but UK 14304-induced GH release was not affected. Hexamethonium 33-46 gonadotropin releasing hormone receptor Rattus norvegicus 78-80 7694432-3 1993 Pretreatment of the animals with hexamethonium significantly reduced GAL- and GHRH-induced GH secretion, but UK 14304-induced GH release was not affected. Hexamethonium 33-46 gonadotropin releasing hormone receptor Rattus norvegicus 91-93 8365651-8 1993 On the contrary, the ganglion blocker significantly (P < 0.01) reduced plasma VIP levels in response to intraduodenal HCl (maximum response 320 +/- 74% in untreated vs 184 +/- 44% in hexamethonium-treated animals). Hexamethonium 186-199 VIP peptides Oryctolagus cuniculus 81-84 8447490-4 1993 During autonomic blockade with methscopolamine and hexamethonium, the pressor sensitivities to AVP and [Phe2,Orn8]oxytocin were similarly increased. Hexamethonium 51-64 arginine vasopressin Rattus norvegicus 95-98 1397041-4 1992 The infusion of single doses of ANGII in control, adrenalectomized, guanethidine-treated and hexamethonium-treated rats dose dependently increased MAP to similar maxima; ED50 value was increased by adrenalectomy but unaffected by guanethidine nor hexamethonium. Hexamethonium 93-106 angiotensinogen Rattus norvegicus 32-37 8093875-4 1993 Intracolonic infusion of a mixture of tryptophan and phenylalanine (Trp+Phe; 100 mM; 200 ml/h) resulted in a significant release of PYY [integrated PYY release, 74.5 +/- 14.0 ng (0-120 min)/ml], which was not affected by iv atropine, hexamethonium, or propranolol treatment. Hexamethonium 234-247 peptide YY Canis lupus familiaris 132-135 1397041-4 1992 The infusion of single doses of ANGII in control, adrenalectomized, guanethidine-treated and hexamethonium-treated rats dose dependently increased MAP to similar maxima; ED50 value was increased by adrenalectomy but unaffected by guanethidine nor hexamethonium. Hexamethonium 247-260 angiotensinogen Rattus norvegicus 32-37 1397041-7 1992 In hexamethonium-treated rats, ANGII also dose relatedly increased MCFP which reached similar maximum as that in control rats, but the ED50 value was reduced. Hexamethonium 3-16 angiotensinogen Rattus norvegicus 31-36 1355917-13 1992 In a supplementary experiment, to evaluate the role of the autonomic nervous system in plasma NPY responses, treatment with the ganglion blocker hexamethonium was shown to significantly attenuate stress-induced changes in NPY, NE, and E. Hexamethonium 145-158 neuropeptide Y Rattus norvegicus 94-97 1422856-7 1992 c-fos expression was substantially attenuated in the superficial gray layer of superior colliculus, medial terminal nucleus of the accessory optic tract, and the interpeduncular nucleus by pretreatment with the centrally acting nicotine antagonist mecamylamine, 5 mg/kg IP, but not with the peripherally acting antagonist hexamethonium, 4 mg/kg IP. Hexamethonium 322-335 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 0-5 1355917-13 1992 In a supplementary experiment, to evaluate the role of the autonomic nervous system in plasma NPY responses, treatment with the ganglion blocker hexamethonium was shown to significantly attenuate stress-induced changes in NPY, NE, and E. Hexamethonium 145-158 neuropeptide Y Rattus norvegicus 222-225 1579660-9 1992 Further evidence for a nicotinic component in the regulation of NPY-IR secretion was obtained by the finding of hexamethonium-induced reduction in basal secretion and stimulation of secretion by 1,1-dimethyl-4-phenyl-piperazinium (DMPP). Hexamethonium 112-125 neuropeptide Y Rattus norvegicus 64-67 1377730-5 1992 Also acetylcholine infusion causes a significant release of SP and NKA after infusion of both atropine and phentolamine (to 172 +/- 56% and 232 +/- 69% of basal release, n = 7), an effect that was abolished by hexamethonium infusion. Hexamethonium 210-223 tachykinin precursor 1 Homo sapiens 60-62 1377730-5 1992 Also acetylcholine infusion causes a significant release of SP and NKA after infusion of both atropine and phentolamine (to 172 +/- 56% and 232 +/- 69% of basal release, n = 7), an effect that was abolished by hexamethonium infusion. Hexamethonium 210-223 tachykinin precursor 1 Homo sapiens 67-70 1529272-6 1992 The inhibitory effect of PACAP was not affected by hexamethonium and was additive to the inhibitory effect of atropine and pirenzepine. Hexamethonium 51-64 adenylate cyclase activating polypeptide 1 Rattus norvegicus 25-30 1347640-6 1992 The marginal effects of large doses of nicotine on both cAMP accumulation and TH induction were blocked completely by hexamethonium but were also partially inhibited by the VIP antagonist [p-chloro-D-Phe6,Leu17]-VIP. Hexamethonium 118-131 tyrosine hydroxylase Bos taurus 78-80 1347741-4 1992 PP only increased by 31 +/- 10 pg/ml during similar hypoglycemia in 7 hexamethonium-treated rats (P less than 0.01 vs. control animals). Hexamethonium 70-83 pancreatic polypeptide Rattus norvegicus 0-2 1379491-5 1992 Ganglionic blockade by hexamethonium markedly inhibited Ache activity in adrenals of non-immobilized and of immobilized mice. Hexamethonium 23-36 acetylcholinesterase Mus musculus 56-60 1937665-5 1991 Correspondingly, maximum response to hexamethonium bromide, a ganglion blocker, was greater in sodium chloride-loaded angiotensin II rats (77.7 +/- 4.6 mm Hg) than that in angiotensin II (59.7 +/- 5.1 mm Hg) or in sodium citrate-loaded angiotensin II (57.7 +/- 4.2 mm Hg) rats. Hexamethonium 37-58 angiotensinogen Rattus norvegicus 118-132 1351787-2 1992 Mean blood pressure (MBP was maintained at a level of 100 mmHg by continuous infusion of methoxamine and hexamethonium to block autonomic outflow. Hexamethonium 105-118 myelin basic protein Rattus norvegicus 21-24 1729436-9 1992 In contrast, the stimulus-induced expression of Fos immunoreactivity was inhibited, but not abolished, by hexamethonium, which limited the spread of activation within the submucosal plexus and completely prevented expression of Fos immunoreactivity by myenteric neurons in response to mucosal puffs of N2. Hexamethonium 106-119 proto-oncogene c-Fos Cavia porcellus 48-51 1729436-9 1992 In contrast, the stimulus-induced expression of Fos immunoreactivity was inhibited, but not abolished, by hexamethonium, which limited the spread of activation within the submucosal plexus and completely prevented expression of Fos immunoreactivity by myenteric neurons in response to mucosal puffs of N2. Hexamethonium 106-119 proto-oncogene c-Fos Cavia porcellus 228-231 1687814-5 1991 In the presence of hexamethonium, the pressor effect of NPY was enhanced, the lack of MCFP effect remained and the bradycardic effect was markedly attenuated. Hexamethonium 19-32 neuropeptide Y Rattus norvegicus 56-59 1731050-9 1992 In the presence of verapamil, ET-1 markedly raised MCFP, and this was abolished by concurrent treatment with either hexamethonium or phentolamine. Hexamethonium 116-129 endothelin 1 Rattus norvegicus 30-34 1682196-6 1991 Hexamethonium markedly reduced the ANS response to insulin injection (delta EPI +2130 +/- 600 pM, P less than 0.025 vs. control) despite a similar fall of plasma glucose (delta -4.1 +/- 0.2 mM) and a lower nadir (0.6 +/- 0.1 mM). Hexamethonium 0-13 insulin Canis lupus familiaris 51-58 1681736-5 1991 Pretreatment with atropine or hexamethonium antagonized GB responses to low doses of CCK-8 (2.5-5 ng.kg-1.min-1) but had no effect on doses greater than 10 ng.kg-1.min-1. Hexamethonium 30-43 cholecystokinin Cavia porcellus 85-88 1715014-4 1991 The apparent mean open time of the AChR channel, as estimated from the power density spectrum of the ACh-induced current fluctuations at -90 mV, was not decreased by 2 microM (+)-sparteine, in contrast to what was observed with hexamethonium, the well known open-channel blocker for ganglionic AChRs. Hexamethonium 228-241 cholinergic receptor nicotinic alpha 2 subunit Rattus norvegicus 35-39 1678851-6 1991 The nicotinic receptor antagonists hexamethonium and mecamylamine partially inhibit the nicotine-mediated stimulation of the tyrosine hydroxylase gene. Hexamethonium 35-48 tyrosine hydroxylase Rattus norvegicus 125-145 1717869-4 1991 Pretreatment with HEX (3 or 15 mg/kg BW), TEA (15 mg/kg BW) or PIR (0.5 mg/kg BW) significantly reduced the GAL-induced GH secretion. Hexamethonium 18-21 galanin and GMAP prepropeptide Rattus norvegicus 108-111 1717869-6 1991 reversed the inhibition of GAL-induced GH secretion by HEX. Hexamethonium 55-58 galanin and GMAP prepropeptide Rattus norvegicus 27-30 1681990-5 1991 Acetylcholine at concentrations of 1 to 100 nM caused a dose-dependent, rapid increase in AVP, whereas AVP release induced by 10 nM acetylcholine was completely suppressed by the combined presence of 10 microM hexamethonium, a nicotinic receptor antagonist, and 50 microM atropine, a muscarinic receptor antagonist. Hexamethonium 210-223 arginine vasopressin Rattus norvegicus 90-93 1681990-5 1991 Acetylcholine at concentrations of 1 to 100 nM caused a dose-dependent, rapid increase in AVP, whereas AVP release induced by 10 nM acetylcholine was completely suppressed by the combined presence of 10 microM hexamethonium, a nicotinic receptor antagonist, and 50 microM atropine, a muscarinic receptor antagonist. Hexamethonium 210-223 arginine vasopressin Rattus norvegicus 103-106 1674644-8 1991 Ganglionic blockade with hexamethonium bromide prevented the effect of ANG II injection in the RVLM. Hexamethonium 25-46 angiotensinogen Rattus norvegicus 71-77 1848199-3 1991 Peptide YY [0.1-1000 nmol/L; concentration of half-maximal effect (EC50), 6 nmol/L] caused concentration-dependent relaxation of longitudinally oriented muscle strips that was unaffected by hexamethonium but was blocked by atropine and tetrodotoxin, suggesting that the peptide inhibited postganglionic cholinergic neurotransmission. Hexamethonium 190-203 peptide YY Cavia porcellus 0-10 1981173-5 1990 The cardioacceleration elicited by intrathecal CGRP was attenuated by intrathecal lidocaine administration and by combined bilateral vagotomy/hexamethonium treatment, but not by either treatment alone. Hexamethonium 142-155 calcitonin-related polypeptide alpha Rattus norvegicus 47-51 20504743-3 1991 Guanethidine and hexamethonium pretreatment significantly reduced the increase of MBP induced by ET-1 but was inactive in antagonizing inhibition of SMR. Hexamethonium 17-30 endothelin 1 Rattus norvegicus 97-101 1979353-5 1990 The AChE inhibitors eserine and hexamethonium were competitive inhibitors of the membrane-bound enzyme, whereas lidocaine was a noncompetitive inhibitor; these results were comparable to the effect of these inhibitors on diaphragm muscle AChE. Hexamethonium 32-45 acetylcholinesterase Bos taurus 4-8 1977325-5 1990 Hexamethonium blocked the changes in HR in response to VIC, whereas the ganglionic blocker, meclofenamate, or glybenclamide had no effect on changes in AP, SVR, and PVR elicited by the peptide. Hexamethonium 0-13 endothelin 2 Mus musculus 55-58 1970534-10 1990 In the acute studies in anesthetized animals, an intravenous bolus dose of CCK-OP (800 ng/kg) caused a substantial increase in SO spike-burst rate that was antagonized by CR1409 but not by atropine, hexamethonium, methysergide, L364718, or TTX. Hexamethonium 199-212 cholecystokinin Homo sapiens 75-78 1972607-5 1990 Tetrodotoxin, hexamethonium and methionine enkephalin inhibited both the induced VIP release and the secretory response. Hexamethonium 14-27 vasoactive intestinal peptide Homo sapiens 81-84 2113409-4 1990 administration of TRH (0.6 and 3 nmol) at the T8-10 vertebral level resulted in a dose-related increase in epinephrine (E), norepinephrine (NE), and glucose levels, which was suppressed by prior administration of the ganglionic blocker, hexamethonium (1.5 mg/100 g b. Hexamethonium 237-250 thyrotropin releasing hormone Rattus norvegicus 18-21 2162234-4 1990 The hypertensive effect of intrathecal and intravenous Leu-Enk administration was blocked by prior systemic administration (10 mg/kg) of the nicotinic ganglion blocker hexamethonium, suggesting that the effect was mediated via sympathetic activation. Hexamethonium 168-181 proenkephalin Rattus norvegicus 59-62 1967914-5 1990 Since hexamethonium almost completely blocked both insulin and glucagon responses to stimulation, the effects are not likely to have resulted from inadvertent antidromic excitation of vagal afferents. Hexamethonium 6-19 insulin Homo sapiens 51-58 1972192-10 1990 Bradykinin-induced stimulation of tracheal ciliary beat frequency is blocked by hexamethonium bromide, ipratropium bromide or indomethacin. Hexamethonium 80-101 kininogen 1 Canis lupus familiaris 0-10 1981792-3 1990 When arginine vasopressin was infused intravenously at a rate of 12.5 ng/(kg.min), the increase in hindquarter resistance, calculated as arterial pressure divided by hindquarter flow, was significantly (p less than 0.005) augmented after ganglionic blockade with hexamethonium in SHR but not in NCR. Hexamethonium 263-276 arginine vasopressin Rattus norvegicus 14-25 2113965-6 1990 The responses to ET-3 were abolished by hexamethonium chloride, but were not conspicuously altered by arginine vasopressin antagonist or angiotensin II antagonist. Hexamethonium 40-62 endothelin 3 Rattus norvegicus 17-21 2314482-5 1990 When the medium contained calcium (catechol-O-methyl transferase inhibited, all other mechanisms intact), 100 (but not 10) mumol/l DMPP induced a hexamethonium-sensitive release of 3H-noradrenaline of short duration. Hexamethonium 146-159 catechol-O-methyltransferase Rattus norvegicus 35-64 35231469-4 2022 Nicotine-induced depression in sensory stimulation-evoked MLI-PC synaptic transmission was abolished by either a non-selective nAChR blocker, hexamethonium, or the alpha7-nAChR antagonist methyllycaconitine (MLA), but not the selective alpha4beta2-nAChR antagonist dihydro-beta-erythroidine. Hexamethonium 142-155 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 127-132 34924113-4 2022 A 100 muM of nicotine-induced increase in neurite numbers depended on the exposure time and was inhibited by treatment with the nAChR antagonist hexamethonium (Hex) and alpha7 nAChR antagonist alpha-bungarotoxin (alpha-Bgtx). Hexamethonium 145-158 cholinergic receptor nicotinic beta 1 subunit Rattus norvegicus 128-133 34924113-4 2022 A 100 muM of nicotine-induced increase in neurite numbers depended on the exposure time and was inhibited by treatment with the nAChR antagonist hexamethonium (Hex) and alpha7 nAChR antagonist alpha-bungarotoxin (alpha-Bgtx). Hexamethonium 160-163 cholinergic receptor nicotinic beta 1 subunit Rattus norvegicus 128-133 34273166-11 2021 Using nicotinic acetylcholine receptor (nAChR) blockers alpha-bungarotoxin and hexamethonium bromide we found that the effects of nicotine on intracellular Ca2+ and oxidative stress were mediated by alpha7 and alpha3 nAChR. Hexamethonium 79-100 cholinergic receptor nicotinic alpha 4 subunit Homo sapiens 6-38 34273166-11 2021 Using nicotinic acetylcholine receptor (nAChR) blockers alpha-bungarotoxin and hexamethonium bromide we found that the effects of nicotine on intracellular Ca2+ and oxidative stress were mediated by alpha7 and alpha3 nAChR. Hexamethonium 79-100 cholinergic receptor nicotinic alpha 4 subunit Homo sapiens 40-45 35231469-4 2022 Nicotine-induced depression in sensory stimulation-evoked MLI-PC synaptic transmission was abolished by either a non-selective nAChR blocker, hexamethonium, or the alpha7-nAChR antagonist methyllycaconitine (MLA), but not the selective alpha4beta2-nAChR antagonist dihydro-beta-erythroidine. Hexamethonium 142-155 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 248-253 2570597-5 1989 The reduction of mBP by hexamethonium injections was significantly larger in sham-operated DOCA/salt-treated rats than those of lesioned DOCA/salt rats. Hexamethonium 24-37 myelin basic protein Mus musculus 17-20 2482449-13 1989 Although the bradycardia elicited by [beta-Asp4, MePhe7]NKB (4-10) (32.5 nmol/kg) was also blocked by hexamethonium, methylatropine, and by bilateral vagotomy, it remained unaffected after indomethacin, or in rats pretreated with either capsaicin or compound 48/80. Hexamethonium 102-115 tachykinin precursor 3 Rattus norvegicus 56-59 2569919-8 1989 The responses to GLU (10 pmol) and TRH (10 pmol) were abolished by hexamethonium and vagotomy; atropine abolished the effect of TRH and attenuated that of GLU. Hexamethonium 67-80 thyrotropin releasing hormone Rattus norvegicus 35-38 2475029-3 1989 VIP release was markedly reduced by tetrodotoxin, perfusion with Ca-free medium, or by hexamethonium but not by atropine. Hexamethonium 87-100 vasoactive intestinal peptide Canis lupus familiaris 0-3 2472074-5 1989 Prior close intra-arterial administration of hexamethonium significantly enhanced the colonic motor response to substance P. Hexamethonium 45-58 tachykinin precursor 1 Homo sapiens 112-123 3259432-8 1988 The tachycardia response to central CGRP was attenuated by pretreatment with propranolol or hexamethonium, indicating that the heart rate response was mediated, in part, through increases in cardiac sympathetic tone. Hexamethonium 92-105 calcitonin-related polypeptide alpha Rattus norvegicus 36-40 2758227-8 1989 This carbachol-evoked increase in acetylcholinesterase release was blocked by hexamethonium but not by atropine. Hexamethonium 78-91 acetylcholinesterase Cavia porcellus 34-54 2912212-4 1989 In contrast, in anesthesized rats the arterial pressor response to intrathecal AVP was blocked by intrathecal V1-ANT, intravenous hexamethonium, and intravenous phenoxybenzamine. Hexamethonium 130-143 arginine vasopressin Rattus norvegicus 79-82 2566102-5 1989 In contrast, the hemodynamic response to hypertonic saline was totally reverted when the vasopressin antagonist was injected in the hexamethonium-pretreated rats. Hexamethonium 132-145 arginine vasopressin Rattus norvegicus 89-100 2568570-4 1989 The administration of hexamethonium attenuated the changes in MAP and heart rate (HR) which occurred in response to alterations in carotid sinus pressure, and abolished the change in plasma IR-ANP. Hexamethonium 22-35 natriuretic peptides A Oryctolagus cuniculus 193-196 2787038-4 1989 Tetrodotoxin and hexamethonium abolished the effects of CGRP on basal short-circuit current whereas atropine did not. Hexamethonium 17-30 calcitonin related polypeptide alpha Homo sapiens 56-60 2977989-8 1988 TRH-induced hyperinsulinemia was abolished by vagotomy and by systemic administration of hexamethonium or atropine. Hexamethonium 89-102 thyrotropin releasing hormone Rattus norvegicus 0-3 2903757-5 1988 The cholinesterase activity in rat diaphragm homogenates was inhibited by hexamethonium. Hexamethonium 74-87 butyrylcholinesterase Rattus norvegicus 4-18 3346065-5 1988 The pressor response to vasopressin, but not to Ang II or norepinephrine, was greater in dexamethasone-treated than in vehicle-treated animals, and this difference became more pronounced in rats that received hexamethonium and MK 421. Hexamethonium 209-222 arginine vasopressin Rattus norvegicus 24-35 2892605-7 1988 Interruption of the sympathetic nervous system and the vascular action of vasopressin with intravenous hexamethonium and d(CH2)5Tyr(Me)arginine vasopressin attenuated the pressor and natriuretic responses to intracerebroventricular high Na+ CSF. Hexamethonium 103-116 arginine vasopressin Rattus norvegicus 74-85 2889122-5 1987 On the other hand, when hexamethonium was infused, naloxone significantly inhibited both the GRP and gastrin responses to electrical vagal stimulation. Hexamethonium 24-37 gastrin releasing peptide Rattus norvegicus 93-96 2889122-5 1987 On the other hand, when hexamethonium was infused, naloxone significantly inhibited both the GRP and gastrin responses to electrical vagal stimulation. Hexamethonium 24-37 gastrin Rattus norvegicus 101-108 2886872-7 1987 When the 9 or 17 mumol Na/g diet were initiated at 2, 4, and 7 weeks of age, the response of blood pressure to hexamethonium administration was blunted in SHR relative to both WKY receiving the same diet, and to control SHR receiving 101 mumol Na/g. Hexamethonium 111-124 sodium voltage-gated channel alpha subunit 7 Rattus norvegicus 23-27 2886872-7 1987 When the 9 or 17 mumol Na/g diet were initiated at 2, 4, and 7 weeks of age, the response of blood pressure to hexamethonium administration was blunted in SHR relative to both WKY receiving the same diet, and to control SHR receiving 101 mumol Na/g. Hexamethonium 111-124 sodium voltage-gated channel alpha subunit 7 Rattus norvegicus 244-248 3031661-2 1987 This inhibitory effect was unaffected by hexamethonium but was abolished by atropine and tetrodotoxin, suggesting that neuropeptide Y is acting via postganglionic cholinergic neurons. Hexamethonium 41-54 pro-neuropeptide Y Cavia porcellus 119-133 3585342-6 1987 Chrg A release on nicotinic stimulation is blocked by D-600 and hexamethonium to the same extent as Met-enkephalin and catecholamine release. Hexamethonium 64-77 chromogranin A Bos taurus 0-6 3577808-6 1987 Hexamethonium, a nicotinic receptor antagonist, inhibited the secretion elicited by the lower but not by the higher dose of NT. Hexamethonium 0-13 neurotensin Homo sapiens 124-126 3826404-5 1987 Ganglionic blockade with methscopolamine and hexamethonium resulted in nearly a 60-fold enhancement of vasopressin pressor sensitivity. Hexamethonium 45-58 arginine vasopressin Rattus norvegicus 103-114 2883103-3 1987 Pretreatment subcutaneously with a ganglion-blocking dose of hexamethonium (10 mg/kg), however, inhibited nicotine-stimulated acid output and ethanol-evoked somatostatin secretion but not ethanol-induced gastrin release. Hexamethonium 61-74 somatostatin Rattus norvegicus 157-169 2437546-8 1987 Atropine significantly reduced, and hexamethonium abolished this VIP-output elicited by parasympathetic nerve stimulation. Hexamethonium 36-49 VIP peptides Oryctolagus cuniculus 65-68 2875603-4 1986 injections of alpha, beta-methylene ATP (mATP) induced colonic and rectal contractions which were resistant to atropine, hexamethonium and indomethacin, as well as to the nerve blocking agent tetrodotoxin. Hexamethonium 121-134 solute carrier family 45, member 2 Mus musculus 36-39 3794328-5 1986 Ganglionic blockade with hexamethonium and atropine produced equivalent decreases in arterial pressure and increases in plasma vasopressin concentration in the two groups of rats. Hexamethonium 25-38 arginine vasopressin Rattus norvegicus 127-138 3792443-4 1986 Responses to motilin were partially inhibited by hexamethonium perfusion (15 micrograms/ml) suggesting that motilin acts, in part, on preganglionic neural elements proximal to nicotinic cholinergic synapses within the enteric nervous system. Hexamethonium 49-62 motilin Canis lupus familiaris 108-115 2874742-3 1986 Hexamethonium did, however, block the increase in blood pressure, the decrease in heart rate, and the very small elevation in the plasma vasopressin concentration induced by nicotine (10 micrograms icv). Hexamethonium 0-13 arginine vasopressin Rattus norvegicus 137-148 2425970-9 1986 sec-1) and the estimated dissociation (kb = 0.24-0.29 sec-1) rate constants derived from a three-state sequential model for block by hexamethonium were independent of the membrane potential. Hexamethonium 133-146 secretory blood group 1, pseudogene Homo sapiens 54-59 2425187-6 1986 In the second study, Ang II-neural interactions were examined by treating 12- to 14-day postligation hypertensive rats with captopril or with hexamethonium, a ganglionic blocker, followed by captopril. Hexamethonium 142-155 angiotensinogen Rattus norvegicus 21-27 3013108-5 1986 Inhibition of clonidine-induced increase in plasma cyclic GMP by yohimbine, hexamethonium and atropine, but not by prazosin suggests that the effect of clonidine is mediated by the central alpha 2-adrenoceptors, activating the muscarinic receptor-linked guanylate cyclase through the stimulation of vagal activity. Hexamethonium 76-89 5'-nucleotidase, cytosolic II Mus musculus 58-61 2880306-5 1986 Hexamethonium, but not atropine, prevented the increase in VP release produced by increased osmolality of the hypothalamus side culture medium. Hexamethonium 0-13 arginine vasopressin Rattus norvegicus 59-61 2579749-9 1985 Peripheral alpha-adrenoceptor blockade with prazosin or ganglion blockade with hexamethonium inhibited the central angiotensin II pressor responses only in combination with vasopressin receptor blockade. Hexamethonium 79-92 angiotensinogen Rattus norvegicus 115-129 3907806-5 1985 At 16 weeks of age, hexamethonium caused potentiation of the blood pressure response to noradrenaline and angiotensin II, but to the same degree in the two strains. Hexamethonium 20-33 angiotensinogen Rattus norvegicus 106-120 4018497-10 1985 The LES response to motilin was abolished by hexamethonium and significantly antagonized by atropine and 4-diphenylacetoxy-N-methylpiperidine methiodide, but was not affected by pirenzepine, phentolamine, or naloxone. Hexamethonium 45-58 motilin Homo sapiens 20-27 2858978-5 1985 The infusion of hexamethonium bromide at a concentration of 10(-4) M significantly suppressed GRP release but did not affect gastrin secretion in response to vagal stimulation. Hexamethonium 16-37 gastrin releasing peptide Rattus norvegicus 94-97 6142392-2 1984 Tetrodotoxin infused intraarterially blocked field stimulated contractions and abolished the response to motilin as did treatment with a combination of hexamethonium and atropine. Hexamethonium 152-165 motilin Canis lupus familiaris 105-112 6696102-5 1984 The enhanced vasoconstrictor responses to carotid infusions of ANG II were significantly attenuated by systemic hexamethonium or central saralasin. Hexamethonium 112-125 angiotensinogen Rattus norvegicus 63-69 6150993-6 1984 Pre-treatment with hexamethonium completely abolished the rise in plasma neuropeptide Y concentrations. Hexamethonium 19-32 neuropeptide Y Bos taurus 73-87 6150485-9 1984 The nicotinic antagonist hexamethonium reduced the increase in 32P incorporation into tyrosine hydroxylase by about 50%, while the muscarinic antagonist atropine had no effect. Hexamethonium 25-38 tyrosine hydroxylase Rattus norvegicus 86-106 6326156-4 1984 Intravenous infusion of ANF in the bilaterally nephrectomized, hexamethonium-treated rat produces only a small transient pressor response, probably due to potentiation of endogenous norepinephrine. Hexamethonium 63-76 natriuretic peptide A Rattus norvegicus 24-27 6142392-4 1984 Hexamethonium alone similarly increased the dose of motilin required in the jejunum, but not for the ileum. Hexamethonium 0-13 motilin Canis lupus familiaris 52-59 6679787-2 1983 These derivatives of hexamethonium and decamethonium manifested reversible inhibition (Ki approximately 100-1 microM) and irreversible alkylating activity (kII approximately 10(2) M-1 . Hexamethonium 21-34 myoregulin Homo sapiens 180-183 6139157-5 1983 Either hexamethonium or atropine blocked IR motilin release induced by stimulation of intrinsic or extrinsic nerves while only atropine inhibited the release induced by intraarterial carbachol. Hexamethonium 7-20 motilin Canis lupus familiaris 44-51 6196809-6 1983 The vagally induced pyloric contraction was noncholinergic, nonadrenergic, but sensitive to ganglionic blockade (hexamethonium) or the SP analogue, indicating involvement of SP in a peptidergic pathway to the sphincter. Hexamethonium 113-126 tachykinin precursor 1 Homo sapiens 174-176 6196809-9 1983 injection of SP, was sensitive to atropine or the SP analogue but hexamethonium resistant. Hexamethonium 66-79 tachykinin precursor 1 Homo sapiens 13-15 6138759-1 1983 In conscious dogs with gastric fistula and platinum electrodes on the antrum, duodenum and jejunum, IV atropine 100 micrograms/kg/hr and hexamethonium 10 mg/kg/hr, blocked cyclic increases in fasting plasma motilin concentration (PMC) and spontaneous migrating myoelectric complexes (MMCs) of both antrum and duodenum. Hexamethonium 137-150 motilin Canis lupus familiaris 207-214 6136311-5 1983 A simultaneous perfusion of hexamethonium (1.9 x 10(-4) M/min) blocked ACh-induced VIP release. Hexamethonium 28-41 vasoactive intestinal peptide Rattus norvegicus 83-86 6191240-3 1983 The results show that the hypotensive activity of NT and of compound 48/80 (C48/80), in contrast to that of histamine, of 5-hydroxytryptamine and of hexamethonium, is markedly reduced, especially for NT, in nephrectomized as compared to sham operated rats. Hexamethonium 149-162 neurotensin Rattus norvegicus 50-52 6296363-5 1983 The increase in plasma cyclic GMP elicited by morphine was abolished by vagotomy and pretreatment with hexamethonium and atropine and was partly inhibited by pretreatment with phentolamine. Hexamethonium 103-116 5'-nucleotidase, cytosolic II Mus musculus 30-33 6189365-0 1982 VIP as a mediator of hexamethonium-sensitive, atropine-resistant vasodilation in the cat tongue. Hexamethonium 21-34 vasoactive intestinal peptide Homo sapiens 0-3 7153911-4 1982 Efferent stimulation of the pelvic nerve caused an increase in the release of VIP, which was unaffected by atropine and adrenoceptor antagonists, but completely abolished by hexamethonium. Hexamethonium 174-187 vasoactive intestinal peptide Felis catus 78-81 7153911-6 1982 Efferent stimulation of the hypogastric nerves induced a marked increase in the release of VIP, which was blocked by hexamethonium. Hexamethonium 117-130 vasoactive intestinal peptide Felis catus 91-94 6124477-3 1982 The gastrin response was abolished by hexamethonium but only partly inhibited (35% at the higher dose of 1,1-dimethyl-4-phenylpiperazinium) by atropine. Hexamethonium 38-51 gastrin Rattus norvegicus 4-11 6181515-3 1982 Antibodies produced in rabbits to a conjugate of bovine serum albumin and a derivative of BisQ mimicked the binding characteristics of the AcChoR with respect to the order of binding of a variety of agonists and to the preferred recognition of decamethonium ion (an agonist) over hexamethonium ion (an antagonist). Hexamethonium 280-293 albumin Oryctolagus cuniculus 56-69 7127212-3 1982 On the other hand, blockade of nicotinic receptors by hexamethonium treatment obliterated I gastrin release induced by stimulation of the extrinsic nerves but only reduced motility. Hexamethonium 54-67 gastrin Canis lupus familiaris 92-99 7127212-5 1982 Since hexamethonium treatment only slightly reduced both I gastrin release and motility and atropinization eliminated both during field stimulation, the presence of a muscarinic receptor in the final pathway for each is proposed. Hexamethonium 6-19 gastrin Canis lupus familiaris 59-66 6778689-1 1981 A tetrodotoxin- and hexamethonium-sensitive response to thyrotropin-releasing hormone (TRH), an in vitro contraction, first appeared in the duodenum of the 3 day old rat, was increased by day 16, decreased there-after and was extinguished after weaning. Hexamethonium 20-33 thyrotropin releasing hormone Rattus norvegicus 56-85 6115624-3 1981 Alpha adrenoceptor antagonists, hexamethonium and 6-hydroxydopamine diminished the effectiveness of low acetylcholine concentrations on normal and castrated preparations of the epididymal portion of isolated rat vas deferens, but did not influence the maximal response. Hexamethonium 32-45 arginine vasopressin Rattus norvegicus 212-215 6123262-6 1982 Plasma norepinephrine and epinephrine levels were not altered by PGF2 alpha-icv in hexamethonium-treated rats, but plasma vasopressin concentration was markedly elevated in all hexamethonium-infused rats. Hexamethonium 177-190 arginine vasopressin Rattus norvegicus 122-133 7045869-6 1982 Hexamethonium, a nicotinic antagonist, at 1 microM abolished the acetylcholine-induced increment in LH-RH release. Hexamethonium 0-13 gonadotropin releasing hormone 1 Rattus norvegicus 100-105 6778689-1 1981 A tetrodotoxin- and hexamethonium-sensitive response to thyrotropin-releasing hormone (TRH), an in vitro contraction, first appeared in the duodenum of the 3 day old rat, was increased by day 16, decreased there-after and was extinguished after weaning. Hexamethonium 20-33 thyrotropin releasing hormone Rattus norvegicus 87-90 7345899-15 1981 Hexamethonium treatment abolished both the vasodilation, the secretion and the VIP release seen during parasympathetic nerve stimulation implying that it was preganglionic and that the preganglionic transmitter is acetylcholine which activates postganglionic transmitter is acetylcholine which activates postganglionic neurons via nicotinic receptors. Hexamethonium 0-13 vasoactive intestinal peptide Felis catus 79-82 7470728-2 1980 2 Veratridine (100 microM) and excess K+ (56 mM) caused secretion of catecholamine and dopamine-beta-hydroxylase (DBH) activity in the venous effluents in the presence of atropine (30 microM) and hexamethonium (2 mM). Hexamethonium 196-209 dopamine beta-hydroxylase Cavia porcellus 87-112 7439634-6 1980 Tetrodotoxin and hexamethonium, but not atropine, inhibited oxytocin-stimulted release of VIP by 80% and 60% respectively. Hexamethonium 17-30 vasoactive intestinal peptide Canis lupus familiaris 90-93 7439634-8 1980 Hexamethonium strongly inhibited neostigmine-stimulated release of VIP. Hexamethonium 0-13 vasoactive intestinal peptide Canis lupus familiaris 67-70 7440712-5 1980 The effect of OP-CCK on the gallbladder was partially blocked by tetrodotoxin (P < 0.02), hexamethonium alone (P < 0.05), or a combination of hexamethonium and atropine (P < 0.01). Hexamethonium 93-106 cholecystokinin Canis lupus familiaris 17-20 7440712-5 1980 The effect of OP-CCK on the gallbladder was partially blocked by tetrodotoxin (P < 0.02), hexamethonium alone (P < 0.05), or a combination of hexamethonium and atropine (P < 0.01). Hexamethonium 148-161 cholecystokinin Canis lupus familiaris 17-20 7470728-2 1980 2 Veratridine (100 microM) and excess K+ (56 mM) caused secretion of catecholamine and dopamine-beta-hydroxylase (DBH) activity in the venous effluents in the presence of atropine (30 microM) and hexamethonium (2 mM). Hexamethonium 196-209 dopamine beta-hydroxylase Cavia porcellus 114-117 456315-2 1979 Nicotinic blocking agents, hexamethonium, tetraethylammonium chloride, and trimethaphan, blocked VP release in response to the addition of sufficient NaCl to yield a 10 mosm/kg H2O increase in culture medium osmolality. Hexamethonium 27-40 arginine vasopressin Rattus norvegicus 97-99 119692-5 1979 The DA releasing effect of TRH was completely blocked by cholinergic blockers (scopolamine, hexamethonium and hemicholinium), Ca2+ chelator(EGTA), Ca2+ antagonist(CoCl2) and Ca2+ influx blocker(D-600) or by the removal of Ca2+ from the medium. Hexamethonium 92-105 thyrotropin releasing hormone Rattus norvegicus 27-30 191573-10 1977 This PSP is blocked by 10(-4) g/ml hexamethonium and mimicked by a Na-dependent ACh response. Hexamethonium 35-48 microseminoprotein beta Homo sapiens 5-8 436724-2 1979 Nicotinic antagonists, hexamethonium, tetraethylammonium chloride, and trimethaphan blocked VP release in response to acetylcholine and nicotine. Hexamethonium 23-36 arginine vasopressin Rattus norvegicus 92-94 874847-0 1977 Effect of hexamethonium on the release of vasopressin by nicotine and carotid occlusion [proceedings]. Hexamethonium 10-23 arginine vasopressin Homo sapiens 42-53 1017712-6 1976 Hexamethonium 2 mg/kg resulted in both a diminished rise in LES pressure and the disappearance of contractions after motilin. Hexamethonium 0-13 motilin Canis lupus familiaris 117-124 1017712-7 1976 Hexamethonium and atropine together completely abolished the LES response to motilin. Hexamethonium 0-13 motilin Canis lupus familiaris 77-84 1079076-4 1975 Acetylcholine (1-5 pg) caused a dose-dependent release of CRH which was antagonized by hexamethonium (1-10ng) and partially antagonized by atropine (300 pg). Hexamethonium 87-100 corticotropin releasing hormone Rattus norvegicus 58-61 954827-3 1976 The increase in PVR to delta9-THC was significantly reduced by cardiac pacing, and was virtually abolished either by bilateral vagotomy or by pretreatment with hexamethonium. Hexamethonium 160-173 PVR cell adhesion molecule Canis lupus familiaris 16-19 177753-8 1976 In contrast, central administration of other anticholinergic drugs, such as delta-tobocurarine and hexamethonium, reduced ethanol-induced sleep and this effect was additive with TRH. Hexamethonium 99-112 thyrotropin releasing hormone Rattus norvegicus 178-181 1255923-7 1976 Plasma renin activity of the hexamethonium bromide treated dogs was 19.0 +/- 3.5 ng/ml during room air breathing. Hexamethonium 29-50 renin Canis lupus familiaris 7-12 948350-2 1976 The influence of the 2 alkane-bis-onium compounds hexafluorenium (HF1) and hexamethonium (C6) on human plasma cholinesterase (ChE) was studied with respect to the type of inhibition. Hexamethonium 75-88 butyrylcholinesterase Homo sapiens 110-124 1186525-0 1975 Cutaneous microcirculatory responses to insulin administration in the fasted and hexamethonium-treated rabbit, with special regard to peripheral circulating leukocytes. Hexamethonium 81-94 insulin Oryctolagus cuniculus 40-47 166720-7 1975 The anti-curare effect of hexamethonium is abolished in the diaphragm of the rat, guinea-pig and mouse by inhibitors of acetylcholinesterase. Hexamethonium 26-39 acetylcholinesterase Mus musculus 120-140 5768107-0 1969 The effects of pempidine and hexamethonium on release of antidiuretic hormone by nicotine and osmotic stimuli in the cat. Hexamethonium 29-42 arginine vasopressin Homo sapiens 57-77 4447857-4 1974 Hexamethonium did not produce local anaesthesia.7 The results indicate that the facilitated release of noradrenaline after SNS and the inhibition of release after DMPP produced by McN-A-343 and AHR 602 are the result of their combined local anaesthetic action and inhibition of amine uptake. Hexamethonium 0-13 aryl hydrocarbon receptor Oryctolagus cuniculus 194-197 6052783-0 1967 [Experiences with the use of hexamethonium with insulin treatment in psychiatry]. Hexamethonium 29-42 insulin Homo sapiens 48-55 13707726-4 1961 In spinal atropinized rats injected with hexamethonium 5 mg/kg this pressor effect produced by injection of the adrenaline antagonist, compound AT3 [ethylfluoren-9-yl(2-iodoethyl)amine hydriodide], was reduced by prior treatment for five days with 1 mg/kg reserpine. Hexamethonium 41-54 angiotensin II receptor, type 1b Rattus norvegicus 144-147 13627212-0 1959 Pressor effect of subcutaneous renin in dogs, and effect of reserpine, 1-hydrazinophthalazine and hexamethonium on renin hypertension. Hexamethonium 98-111 renin Canis lupus familiaris 115-120 29360991-9 2018 Increased sympathetic activity in sm-STIM1 KO mice was unmasked by apha1-adrenergic receptor inhibitor (prazosin) and by treatment with the ganglion-blocking agent, hexamethonium. Hexamethonium 165-178 stromal interaction molecule 1 Mus musculus 37-42 33456504-8 2021 The muscarinic acetylcholine receptor (mAChR) antagonist atropine (ATR; 100 nM) and the nicotinic acetylcholine receptor (nAChR) antagonist hexamethonium (HEM; 50 microM) were administered 10 min before APC. Hexamethonium 140-153 cholinergic receptor nicotinic alpha 2 subunit Rattus norvegicus 122-127 32337286-13 2020 Finally, four small molecules that could reverse the gene expression induced by thyroid cancer, namely ikarugamycin, adrenosterone, hexamethonium bromide and clofazimine, were obtained in the CMap database. Hexamethonium 132-153 cystatin F Homo sapiens 192-196 14954123-0 1952 Effect of hexamethonium on the response to insulin in animals and man. Hexamethonium 10-23 insulin Homo sapiens 43-50 33384338-8 2021 Cryoelectron microscopy analysis of the HAdV-D56 virion-CD46 complex confirmed the interaction and showed that CD46 binds to the central cavity of hexon trimers. Hexamethonium 147-152 CD46 molecule Homo sapiens 56-60 33384338-8 2021 Cryoelectron microscopy analysis of the HAdV-D56 virion-CD46 complex confirmed the interaction and showed that CD46 binds to the central cavity of hexon trimers. Hexamethonium 147-152 CD46 molecule Homo sapiens 111-115 33146235-9 2020 Administration of hexamethonium, a ganglion blocker, abolished RIP-induced increase in plasma CCK levels and cardioprotective effects. Hexamethonium 18-31 cholecystokinin Rattus norvegicus 94-97 31657686-6 2019 RESULTS: Infusion of apelin into PVN of Wistar-Kyoto (WKY) rats induced chronic increases in systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), plasma norepinephrine (NE) level, maximal depressor response to hexamethonium (Hex), NAD(P)H oxidase activity, superoxide anions levels, and Nox4 expression. Hexamethonium 250-263 apelin Rattus norvegicus 21-27 31657686-6 2019 RESULTS: Infusion of apelin into PVN of Wistar-Kyoto (WKY) rats induced chronic increases in systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), plasma norepinephrine (NE) level, maximal depressor response to hexamethonium (Hex), NAD(P)H oxidase activity, superoxide anions levels, and Nox4 expression. Hexamethonium 265-268 apelin Rattus norvegicus 21-27 31657686-8 2019 Hex, a sympathetic ganglion blocker, inhibited apelin-induced increases in SBP, DBP and MAP. Hexamethonium 0-3 apelin Rattus norvegicus 47-53 31657686-9 2019 SOD overexpression in PVN of SHRs inhibited the apelin-induced increase in SBP, DBP, MAP, plasma NE level, and maximal depressor response to Hex. Hexamethonium 141-144 apelin Rattus norvegicus 48-54 31657686-10 2019 PVN Nox4 knockdown also attenuated the apelin-induced increase in SBP, DBP, MAP, plasma NE level, and maximal depressor response to Hex. Hexamethonium 132-135 NADPH oxidase 4 Rattus norvegicus 4-8 31657686-10 2019 PVN Nox4 knockdown also attenuated the apelin-induced increase in SBP, DBP, MAP, plasma NE level, and maximal depressor response to Hex. Hexamethonium 132-135 apelin Rattus norvegicus 39-45 27923809-8 2017 We also found that after pretreatment with hexamethonium (n = 8), ICV leptin infusion, during continued ganglionic blockade, completely normalized blood glucose in diabetic rats. Hexamethonium 43-56 leptin Rattus norvegicus 70-76 28935683-14 2018 Short-latency calcium transients were detected in >90% of calcitonin gene-related peptide-immunoreactive neurons to electrical stimulation of hexamethonium-sensitive pathways. Hexamethonium 145-158 calcitonin/calcitonin-related polypeptide, alpha Mus musculus 61-92